NZ711375B2 - Methods for increasing efficacy of folr1 cancer therapy - Google Patents
Methods for increasing efficacy of folr1 cancer therapy Download PDFInfo
- Publication number
- NZ711375B2 NZ711375B2 NZ711375A NZ71137512A NZ711375B2 NZ 711375 B2 NZ711375 B2 NZ 711375B2 NZ 711375 A NZ711375 A NZ 711375A NZ 71137512 A NZ71137512 A NZ 71137512A NZ 711375 B2 NZ711375 B2 NZ 711375B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- folrl
- tumor
- antibody
- staining
- acid sequence
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title claims description 87
- 230000001965 increased Effects 0.000 title description 25
- 238000002560 therapeutic procedure Methods 0.000 title description 14
- 102000004965 antibodies Human genes 0.000 claims abstract description 230
- 108090001123 antibodies Proteins 0.000 claims abstract description 226
- 206010028980 Neoplasm Diseases 0.000 claims description 181
- 238000010186 staining Methods 0.000 claims description 176
- 210000001519 tissues Anatomy 0.000 claims description 147
- 230000014509 gene expression Effects 0.000 claims description 120
- 230000027455 binding Effects 0.000 claims description 79
- 238000001514 detection method Methods 0.000 claims description 62
- 102000038129 antigens Human genes 0.000 claims description 48
- 108091007172 antigens Proteins 0.000 claims description 48
- 238000003364 immunohistochemistry Methods 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 46
- 108010027440 Immunoconjugates Proteins 0.000 claims description 41
- 102000018748 Immunoconjugates Human genes 0.000 claims description 41
- 239000003153 chemical reaction reagent Substances 0.000 claims description 32
- 239000008188 pellet Substances 0.000 claims description 28
- 230000002611 ovarian Effects 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 15
- -1 amino amino Chemical group 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 15
- 229960002685 biotin Drugs 0.000 claims description 15
- 235000020958 biotin Nutrition 0.000 claims description 15
- 239000011616 biotin Substances 0.000 claims description 15
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 14
- 239000002254 cytotoxic agent Substances 0.000 claims description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 10
- 230000001472 cytotoxic Effects 0.000 claims description 9
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 230000002357 endometrial Effects 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 6
- 239000012188 paraffin wax Substances 0.000 claims description 6
- AMRJKAQTDDKMCE-UHFFFAOYSA-N Dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 5
- 241000229754 Iva xanthiifolia Species 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- 229940002612 prodrugs Drugs 0.000 claims description 5
- VQZYZXLBKBUOHE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)butanoate Chemical compound C=1C=CC=NC=1SSC(C)CC(=O)ON1C(=O)CCC1=O VQZYZXLBKBUOHE-UHFFFAOYSA-N 0.000 claims description 4
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000002285 radioactive Effects 0.000 claims description 4
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 4
- 229910052722 tritium Inorganic materials 0.000 claims description 4
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (6R,6aS,8E)-8-ethylidene-3-hydroxy-2,6-dimethoxy-6,6a,7,9-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical class CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 claims description 3
- YACHGFWEQXFSBS-RJXCBBHPSA-N Leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 claims description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 claims description 3
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 210000004303 Peritoneum Anatomy 0.000 claims description 2
- OOUPHXWHXYLQBK-UHFFFAOYSA-M [O-]C(=O)CCC(C)SSC1=CC=CC=N1 Chemical compound [O-]C(=O)CCC(C)SSC1=CC=CC=N1 OOUPHXWHXYLQBK-UHFFFAOYSA-M 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 23
- SXNQAQBMEWMYAU-UHFFFAOYSA-N sulfo butanoate Chemical compound CCCC(=O)OS(O)(=O)=O SXNQAQBMEWMYAU-UHFFFAOYSA-N 0.000 claims 2
- SLMVEZKWNOGJPD-UHFFFAOYSA-M 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound [O-]C(=O)CCCSSC1=CC=CC=N1 SLMVEZKWNOGJPD-UHFFFAOYSA-M 0.000 claims 1
- 101700077824 CNN1 Proteins 0.000 claims 1
- 102100006947 TAGLN Human genes 0.000 claims 1
- 101710025884 TAGLN Proteins 0.000 claims 1
- OWDQCSBZQVISPN-UHFFFAOYSA-M [O-]C(=O)C1=CC=C(C(=O)CI)C=C1NN1C(=O)CCC1=O Chemical compound [O-]C(=O)C1=CC=C(C(=O)CI)C=C1NN1C(=O)CCC1=O OWDQCSBZQVISPN-UHFFFAOYSA-M 0.000 claims 1
- 150000001991 dicarboxylic acids Chemical class 0.000 claims 1
- 229920000406 phosphotungstic acid polymer Polymers 0.000 claims 1
- VKBKSLDOBKBYSW-UHFFFAOYSA-N sulfo pentanoate Chemical compound CCCCC(=O)OS(O)(=O)=O VKBKSLDOBKBYSW-UHFFFAOYSA-N 0.000 claims 1
- 102100011898 FOLR1 Human genes 0.000 abstract description 4
- 101700050183 FOLR1 Proteins 0.000 abstract description 4
- 102000005962 receptors Human genes 0.000 abstract description 3
- 108020003175 receptors Proteins 0.000 abstract description 3
- 230000003432 anti-folate Effects 0.000 abstract description 2
- 239000004052 folic acid antagonist Substances 0.000 abstract description 2
- 210000004027 cells Anatomy 0.000 description 208
- 239000000523 sample Substances 0.000 description 105
- 108050001931 Folate receptor alpha Proteins 0.000 description 51
- 102000010451 Folate receptor alpha Human genes 0.000 description 51
- 238000004166 bioassay Methods 0.000 description 44
- 125000005842 heteroatoms Chemical group 0.000 description 40
- 206010033128 Ovarian cancer Diseases 0.000 description 39
- 239000011230 binding agent Substances 0.000 description 31
- 239000000203 mixture Substances 0.000 description 28
- 210000004881 tumor cells Anatomy 0.000 description 28
- 239000003814 drug Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 201000001539 ovarian carcinoma Diseases 0.000 description 22
- 210000004072 Lung Anatomy 0.000 description 20
- 230000004614 tumor growth Effects 0.000 description 20
- 229940079593 drugs Drugs 0.000 description 19
- 230000035945 sensitivity Effects 0.000 description 19
- 238000010253 intravenous injection Methods 0.000 description 18
- 239000003446 ligand Substances 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 18
- 230000000259 anti-tumor Effects 0.000 description 17
- 201000009030 carcinoma Diseases 0.000 description 17
- 150000002500 ions Chemical class 0.000 description 17
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 17
- 230000001225 therapeutic Effects 0.000 description 17
- 238000007447 staining method Methods 0.000 description 16
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 15
- 210000004379 Membranes Anatomy 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 208000009956 Adenocarcinoma Diseases 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 229940088598 Enzyme Drugs 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 210000003734 Kidney Anatomy 0.000 description 12
- 238000009826 distribution Methods 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
- 239000012472 biological sample Substances 0.000 description 11
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 230000001809 detectable Effects 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 201000005202 lung cancer Diseases 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 102000018358 Immunoglobulins Human genes 0.000 description 9
- 108060003951 Immunoglobulins Proteins 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000000496 Pancreas Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 230000004083 survival Effects 0.000 description 8
- 108090001008 Avidin Proteins 0.000 description 7
- 239000004698 Polyethylene (PE) Substances 0.000 description 7
- 210000003079 Salivary Glands Anatomy 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 229920000023 polynucleotide Polymers 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 230000035693 Fab Effects 0.000 description 6
- 102220460541 SVBP T47D Human genes 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 235000019152 folic acid Nutrition 0.000 description 6
- 239000011724 folic acid Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 230000036678 protein binding Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 210000004369 Blood Anatomy 0.000 description 5
- 229940014144 Folate Drugs 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 229940035295 Ting Drugs 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000001747 exhibiting Effects 0.000 description 5
- 230000000670 limiting Effects 0.000 description 5
- 108010045030 monoclonal antibodies Proteins 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 210000000056 organs Anatomy 0.000 description 5
- 230000036961 partial Effects 0.000 description 5
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 4
- 210000000349 Chromosomes Anatomy 0.000 description 4
- 210000003238 Esophagus Anatomy 0.000 description 4
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108010021466 Mutant Proteins Proteins 0.000 description 4
- 102000008300 Mutant Proteins Human genes 0.000 description 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 4
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 description 4
- 229940072417 Peroxidase Drugs 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 108090000437 Peroxidases Proteins 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- 230000000890 antigenic Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000003247 decreasing Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 101700029224 ftsH Proteins 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 102000005614 monoclonal antibodies Human genes 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 4
- 230000000381 tumorigenic Effects 0.000 description 4
- 231100000588 tumorigenic Toxicity 0.000 description 4
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 description 3
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 3
- 101700027111 3SA0 Proteins 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 210000000481 Breast Anatomy 0.000 description 3
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 3
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 208000005017 Glioblastoma Diseases 0.000 description 3
- 206010027476 Metastasis Diseases 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 3
- 208000004019 Papillary Adenocarcinoma Diseases 0.000 description 3
- VUVGYHUDAICLFK-UHFFFAOYSA-N Perosmic oxide Chemical compound O=[Os](=O)(=O)=O VUVGYHUDAICLFK-UHFFFAOYSA-N 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 210000003932 Urinary Bladder Anatomy 0.000 description 3
- 230000001476 alcoholic Effects 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 101700067609 ctx Proteins 0.000 description 3
- 239000002619 cytotoxin Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 101700043720 folK Proteins 0.000 description 3
- 230000002496 gastric Effects 0.000 description 3
- 230000002055 immunohistochemical Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 108091008117 polyclonal antibodies Proteins 0.000 description 3
- 230000000268 renotropic Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000002195 synergetic Effects 0.000 description 3
- WGMMKWFUXPMTRW-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[(2-bromoacetyl)amino]propanoate Chemical compound BrCC(=O)NCCC(=O)ON1C(=O)CCC1=O WGMMKWFUXPMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- CXNVOWPRHWWCQR-UHFFFAOYSA-N 4-Chloro-o-toluidine Chemical compound CC1=CC(Cl)=CC=C1N CXNVOWPRHWWCQR-UHFFFAOYSA-N 0.000 description 2
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 2
- 208000000409 Breast Neoplasms Diseases 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 210000004436 Chromosomes, Artificial, Bacterial Anatomy 0.000 description 2
- 206010073251 Clear cell renal cell carcinoma Diseases 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N Deoxycytidine triphosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- 230000036947 Dissociation constant Effects 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 210000004696 Endometrium Anatomy 0.000 description 2
- 210000000981 Epithelium Anatomy 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical group C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 2
- 210000003128 Head Anatomy 0.000 description 2
- 210000004754 Hybrid Cells Anatomy 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- 241000282619 Hylobates lar Species 0.000 description 2
- 210000002414 Leg Anatomy 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- FSVCQIDHPKZJSO-UHFFFAOYSA-L Nitro blue tetrazolium chloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 2
- NNPUPCNWEHWRPW-UHFFFAOYSA-M OS(=O)(=O)C(C([O-])=O)CCSSC1=CC=CC=N1 Chemical compound OS(=O)(=O)C(C([O-])=O)CCSSC1=CC=CC=N1 NNPUPCNWEHWRPW-UHFFFAOYSA-M 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 229920002224 Peptide nucleic acid Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 210000004043 Pneumocytes Anatomy 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 210000001533 Respiratory Mucosa Anatomy 0.000 description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N Texas Red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 210000001685 Thyroid Gland Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000000295 complement Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 230000001086 cytosolic Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JORABGDXCIBAFL-UHFFFAOYSA-M iodonitrotetrazolium chloride Chemical compound [Cl-].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C=CC=CC=2)=N1 JORABGDXCIBAFL-UHFFFAOYSA-M 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229920005589 poly(ferrocenylsilane) Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 200000000025 progressive disease Diseases 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 201000010174 renal carcinoma Diseases 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000000717 retained Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NKUZQMZWTZAPSN-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-bromoacetate Chemical compound BrCC(=O)ON1C(=O)CCC1=O NKUZQMZWTZAPSN-UHFFFAOYSA-N 0.000 description 1
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- PMJWDPGOWBRILU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCC(C=C1)=CC=C1N1C(=O)C=CC1=O PMJWDPGOWBRILU-UHFFFAOYSA-N 0.000 description 1
- IHVODYOQUSEYJJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]amino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)C(CC1)CCC1CN1C(=O)C=CC1=O IHVODYOQUSEYJJ-UHFFFAOYSA-N 0.000 description 1
- IPVTTYAHKXZGCQ-QOCHGBHMSA-N (4Z)-3-oxo-4-[(4-sulfonaphthalen-1-yl)hydrazinylidene]naphthalene-2,7-disulfonic acid Chemical compound C1=CC=C2C(N/N=C3/C4=CC=C(C=C4C=C(C3=O)S(=O)(=O)O)S(O)(=O)=O)=CC=C(S(O)(=O)=O)C2=C1 IPVTTYAHKXZGCQ-QOCHGBHMSA-N 0.000 description 1
- PCDQPRRSZKQHHS-XVFCMESISA-N ({[({[(2R,3S,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-XVFCMESISA-N 0.000 description 1
- OJQSISYVGFJJBY-UHFFFAOYSA-N 1-(4-isocyanatophenyl)pyrrole-2,5-dione Chemical compound C1=CC(N=C=O)=CC=C1N1C(=O)C=CC1=O OJQSISYVGFJJBY-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-Diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- GDOCXFCVKYUQIQ-UHFFFAOYSA-N 4-[amino(methoxy)methylidene]cyclohexa-2,5-dien-1-one;hydrochloride Chemical compound Cl.COC(N)=C1C=CC(=O)C=C1 GDOCXFCVKYUQIQ-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WTWSDDKGKIGSJE-UHFFFAOYSA-N 5-(4-aminophenyl)cyclohexa-2,4-diene-1,1,2-triamine;tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.C1C(N)(N)C(N)=CC=C1C1=CC=C(N)C=C1 WTWSDDKGKIGSJE-UHFFFAOYSA-N 0.000 description 1
- KOZWHQPRAOJMBN-ZKWXMUAHSA-N 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanehydrazide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NN)SC[C@@H]21 KOZWHQPRAOJMBN-ZKWXMUAHSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethylcarbazol-3-amine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-M AC1L4ZKD Chemical compound [O-]I(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-M 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 101710032898 ALPI Proteins 0.000 description 1
- 102100013689 ALPI Human genes 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N AMCHA Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 240000000800 Allium ursinum Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- BJDJEJIINKBPHY-UHFFFAOYSA-N BODIPY FL Chemical compound C1=C2C=CC(CCC(O)=O)=[N+]2[B-](F)(F)N2C(C)=CC(C)=C21 BJDJEJIINKBPHY-UHFFFAOYSA-N 0.000 description 1
- RFLLOBSXBJAGST-UHFFFAOYSA-N BODIPY R6G Chemical compound C1=CC(CCC(=O)O)=[N+]([B-](N23)(F)F)C1=CC2=CC=C3C1=CC=CC=C1 RFLLOBSXBJAGST-UHFFFAOYSA-N 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 229960003872 Benzethonium Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 210000001217 Buttocks Anatomy 0.000 description 1
- 229920002574 CR-39 Polymers 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 210000002987 Choroid Plexus Anatomy 0.000 description 1
- 210000003917 Chromosomes, Human Anatomy 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N Deoxyguanosine triphosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 240000003139 Ferula foetida Species 0.000 description 1
- 102000006815 Folate receptors Human genes 0.000 description 1
- 108020005243 Folate receptors Proteins 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- 101700060135 GNMT Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M Gold(I) chloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- VZJFGSRCJCXDSG-UHFFFAOYSA-N Hexamethonium Chemical compound C[N+](C)(C)CCCCCC[N+](C)(C)C VZJFGSRCJCXDSG-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- PDCKRJPYJMCOFO-UHFFFAOYSA-N Imidogen Chemical compound [NH] PDCKRJPYJMCOFO-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 241000575946 Ione Species 0.000 description 1
- 210000004153 Islets of Langerhans Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 240000004841 Meum athamanticum Species 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- CNXZLZNEIYFZGU-UHFFFAOYSA-N N-(4-amino-2,5-diethoxyphenyl)benzamide Chemical compound C1=C(N)C(OCC)=CC(NC(=O)C=2C=CC=CC=2)=C1OCC CNXZLZNEIYFZGU-UHFFFAOYSA-N 0.000 description 1
- NXTVQNIVUKXOIL-UHFFFAOYSA-N N-chlorotoluene-p-sulfonamide Chemical compound CC1=CC=C(S(=O)(=O)NCl)C=C1 NXTVQNIVUKXOIL-UHFFFAOYSA-N 0.000 description 1
- 108091006020 N-glycosylated proteins Proteins 0.000 description 1
- AWZJFZMWSUBJAJ-UHFFFAOYSA-N OG-514 dye Chemical compound OC(=O)CSC1=C(F)C(F)=C(C(O)=O)C(C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)=C1F AWZJFZMWSUBJAJ-UHFFFAOYSA-N 0.000 description 1
- 102100010852 OLR1 Human genes 0.000 description 1
- 101710022920 OLR1 Proteins 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 210000003101 Oviducts Anatomy 0.000 description 1
- 102100002918 PEX19 Human genes 0.000 description 1
- 101700060762 PEX19 Proteins 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N Phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 208000002151 Pleural Effusion Diseases 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- XUARKZBEFFVFRG-UHFFFAOYSA-N Silver sulfide Chemical compound [S-2].[Ag+].[Ag+] XUARKZBEFFVFRG-UHFFFAOYSA-N 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108009000491 Small cell lung cancer Proteins 0.000 description 1
- 231100000632 Spindle poison Toxicity 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 241000282890 Sus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001138 Tears Anatomy 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N Trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 229940045145 Uridine Drugs 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N Uridine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasm Diseases 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- 241000812633 Varicus Species 0.000 description 1
- 241000446304 Vela Species 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 Zidovudine Drugs 0.000 description 1
- PUDCZUQFOPHIGU-UHFFFAOYSA-N [2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]azanium;chloride Chemical compound Cl.C1=C(N)C(C)=CC(N=NC=2C(=CC=CC=2)C)=C1 PUDCZUQFOPHIGU-UHFFFAOYSA-N 0.000 description 1
- IOMLBTHPCVDRHM-UHFFFAOYSA-N [3-[(2,4-dimethylphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound CC1=CC(C)=CC=C1NC(=O)C1=CC2=CC=CC=C2C=C1OP(O)(O)=O IOMLBTHPCVDRHM-UHFFFAOYSA-N 0.000 description 1
- HUXIAXQSTATULQ-UHFFFAOYSA-N [6-bromo-3-[(2-methoxyphenyl)carbamoyl]naphthalen-2-yl] dihydrogen phosphate Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1OP(O)(O)=O HUXIAXQSTATULQ-UHFFFAOYSA-N 0.000 description 1
- 229910052946 acanthite Inorganic materials 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001919 adrenal Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000000183 arugula Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay method Methods 0.000 description 1
- 108010044540 auristatin Proteins 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- IYXMNTLBLQNMLM-UHFFFAOYSA-N benzene-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=C(N)C=C1 IYXMNTLBLQNMLM-UHFFFAOYSA-N 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 description 1
- 230000001085 cytostatic Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-J dATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-J 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- ZGGYGTCPXNDTRV-DAPHBAMLSA-L ferroheme a Chemical compound C1=C2C(C)=C(C=C)C(C=C3N4C(=C5)C(CCC(O)=O)=C3C)=[N+]2[Fe-2]42[N+]3=C5C(CCC(O)=O)=C(C=O)C3=CC3=C(C)C(C(O)CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C1N32 ZGGYGTCPXNDTRV-DAPHBAMLSA-L 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 229950002932 hexamethonium Drugs 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 230000001744 histochemical Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 1
- 235000007635 levomefolic acid Nutrition 0.000 description 1
- 239000011578 levomefolic acid Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000004880 lymph fluids Anatomy 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 108091013906 nucleotide binding proteins Proteins 0.000 description 1
- 102000030264 nucleotide binding proteins Human genes 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- BRJCLSQFZSHLRL-UHFFFAOYSA-N oregon green 488 Chemical compound OC(=O)C1=CC(C(=O)O)=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 BRJCLSQFZSHLRL-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000005298 paramagnetic Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000889 poly(m-phenylene isophthalamide) Polymers 0.000 description 1
- 229920000069 poly(p-phenylene sulfide) Polymers 0.000 description 1
- 229920002745 polystyrene-block- poly(ethylene /butylene) Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000036633 rest Effects 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 229940056910 silver sulfide Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- VOBHRQFELWTZFS-AWLRYRRCSA-K trisodium;(4Z)-3-oxo-4-[(4-sulfonatonaphthalen-1-yl)hydrazinylidene]naphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N/N=C3/C4=CC=C(C=C4C=C(C3=O)S(=O)(=O)[O-])S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 VOBHRQFELWTZFS-AWLRYRRCSA-K 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Abstract
Disclosed is a method of identifying a tumour as sensitive to treatment with an anti-Folate Receptor 1 (FOLR1) antibody.
Description
METHODS FOR SING EFFICACY OF FOLR1 CANCER THERAPY
CROSS-REFERENCE TO RELATED ATIONS
This application is a divisional of New Zealand Application No. 615742, filed on
March 2012, and is related to International Patent Application No.
, filed on 30 March 2012 and claims priority from U.S. Provisional
Application No. 61/471,007, filed on 1 April 2011; each of which is incorporated herein
by reference in its entirety.
BACKGROUND OF THE INVENTION
Field of the Invention
The field of invention generally relates to increasing the efficacy of the treatment
of cancers characterized by the overexpression of human folate receptor 1 (FOLR1).
More ically, the ion concerns more effective treatment of patients
susceptible to or diagnosed with cancer, in which the tumor cells press FOLR1 as
determined by a gene expression assay, with a FOLR1 nist, e.g., a FOLR1
immunoconjugate.
Background Art
Cancer is one of the leading causes of death in the developed world, with over
one million people diagnosed with cancer and 500,000 deaths per year in the United
States alone. Overall it is estimated that more than 1 in 3 people will develop some
form of cancer during their me. There are more than 200 different types of cancer,
four of which—breast, lung, colorectal, and prostate—account for over half of all new
cases (Jemal et al., 2003, Cancer J. Clin. 53:5-26).
Folate or 1 (FOLR1), also known as Folate Receptor-alpha, or Folate
Binding Protein, is an N-glycosylated protein expressed on the plasma membrane of
cells. FOLR1 has a high affinity for folic acid and for l reduced folic acid
derivatives. FOLR1 mediates delivery of the physiological folate, 5-
methyltetrahydrofolate, to the interior of cells.
FOLR1 is overexpressed in a vast majority of ovarian cancers, as well as in
many e, endometrial, pancreatic, renal, lung, and breast cancers, while the
expression of FOLR1 on normal tissues is restricted to the apical membrane of epithelial
cells in the kidney proximal tubules, alveolar pneumocytes of the lung, bladder, testes,
choroid plexus, and thyroid an SD, et al., Cancer Res 52: 3396-3401 (1992);
Antony AC, Annu Rev
[TEXT CONTINUES ON PAGE 2]
- 1a -
Nutr 16: 501-521 ; Kalli KR, et a1. Gynecol Oncol 108: 619—626 (2008)). This
expression pattern of FOLRl makes it a desirable target for FOLRl —directed cancer therapy.
Because ovarian cancer is typically asymptomatic until advanced stage, it is often
diagnosed at a late stage and has poor prognosis when treated with currently ble
procedures, typically chemotherapeutic drugs after al de-bulking (von Gruenigen V et
al., Cancer 112: 2221-2227 (2008); Ayhan A et al., Am J Obstet Gynecol 196: 81 e81-86
(2007); Harry VN et 61]., Obstet Gynecol Surv 64: 548-560 ). Thus, there is a clear
unmet l need for more effective therapeutics for ovarian cancers.
SUMMARY OF THE INVENTION
The present invention is based on the discovery of a dynamic range of expression of
FOLRI in tumor tissue and the discovery that tumors with increased levels of FOLRl
expression are more responsive to treatment with anti-FOLRl antibodies or anti-FOLRl
immunoconjugates. The present invention advantageously permits treatment of patients
who have a greater likelihood of responding to treatment by administering therapeutic
agents, i.e., anti-FOLRl antibodies or anti-FOLRl immunoconjugates, to patients who are
found to have an increased expression level of FOLRl.
The present ion provides a method for identifying a subject pre-disposed to
respond favorably to a Folate Receptor 1 (FOLRl)—targeting anti-cancer therapeutic, the
method comprising detecting FOLRl expression in a tissue sample from the subject.
The present invention also provides a method for increasing the likelihood of
effectiveness of a cancer treatment, the method comprising administering a therapeutically
effective dose of a FOLRl-targeting anti-cancer eutic to a subject, n FOLRI
expression in a tissue sample from the subject has been found to be sed.
The present invention also provides a method for predicting effectiveness of a low—
dose cancer ent, the method comprising administering a therapeutically effective dose
of a FOLRl—targeting anti-cancer therapeutic to a subject, n said subject has been
found to have increased expression of FOLRl in a sample.
In one embodiment, the methods are directed to n carcinoma, non-small cell
lung adenocarcinoma ding bronchioloalveolar carcinoma), renal carcinomas, and
endometrial carcinomas.
In one embodiment, the extent and uniformity of FOLRI sion is detected by
immunohistochemistry (IHC), flow cytometry, or nucleic acid hybridization. in r
embodiment, the level of FOLRl expression is detected by immunohistochemistry. Non-
limiting examples of IHC include IHC methods that distinguish between varying levels of
FOLRI and calibrated IHC methods, such as those described herein. The FOLRl
sion can be scored using an appropriate scoréng , including but not limited to
the scoring methods bed herein. For example, FOLRI expression can be scored using
a calibrated IHC method that includes a range of 0, 1, 2, 3, and 3+ for staining intensity
with 0 being the lowest level of staining intensity and 3+ being the highest level of staining
intensity. Alternatively or additionally, FOLRI sion can be scored using a ated
IHC method that includes a staining uniformity that ranges from focal (<25% of cells
stained), to heterogeneous (25-75% of cells stained), to homogenous (>75% of cells
stained), where focal staining is the least uniform staining and homogeneous is the most
uniform staining.
In a further embodiment, the FOLRI expression in a sample (e.g., a tumor tissue
) is ed and ed to one or more reference samples and the FOLRl
expression in the tissue sample from a subject tumor, xenograft tumor, or cell line has a
FOLRI specific score ating to extent and uniformity of expression as compared to the
one or more reference samples. In various examples, a tissue sample or cell with a level 1,
2, 3 or 3+ FOLRl staining ity with a homogeneous staining pattern is considered to
have increased FOLRl expression; a tissue sample or cell with a level 3 FOLRl staining
intensity with heterogeneous or focal staining patterns is considered to have increased
FOLRl expression. In another embodiment the FOLRI expression in a sample is measured
and compared to one or more reference samples to identify a comparable level of ng.
In one embodiment, the reference sample has a pre-assigned IHC score and/or a pre-
determined antigen per cell (or ABC) number and the n or ABC number for the
sample tissue can be determined based on the comparison.
In one embodiment, the FOLRl expression in a sample (e.g., a tumor tissue sample)
is measured and compared to one or more control samples and the FOLRl expression in the
tissue sample from a subject tumor, xenograft tumor, or cell line has a FOLRl specific score
correlating to extent and uniformity of expression as compared to the one or more control
samples. In one embodiment, the FOLRl expression in the sample is compared to a
negative control sample which demonstrates no or low detectable FOLRI expression. In
another embodiment, the FGLR'E expression in the sample is compared to a ve control
sample having sed FOLRl expressinn {level i, 2, 3. or 3+). In some embodin‘ien‘ts, the
control samples include, but are not limited in a, SW2, SWéZO, T47D, IGRG‘V’J,
300,19 FRI, i-Ielga, or KB cells. In particular embodir‘nents, the control samples include
cells or cell pellets from cells transfected with folate receptor (e.g., 300.19 FRl).
In one embodiment, the FOLRl-targeting anti-cancer therapeutic is a FOLRI
immunoconjugate. In one embodiment, the immunoconjugate ses an anti-FOLRI
dy, a linker, and a cytotoxin.
In a further ment, the anti-FOLRI antibody is huMOVl9. In another
ment, the linker is selected from the group consisting of a cleavable linker, a non~
cleavable linker, a hydrophilic linker, and a dicarboxylic acid based linker. in another
embodiment, the linker is selected from the group consisting: N—succinimidyl 4-(2—
pyridyldithio)pentanoate (SPP) or N—succinimidyl yridyldithio)-2—sulfopentanoate
(sulfo—SPP); inimidyl 4-(2-pyn'dyldithio)butanoate (SPDB) or N-succinimidyl 4-(2—
pyridyldithio)-2—sulfobutanoate (sulfo-SPDB); N—succinimidyl 4-(maleimidomethyl)
cyclohexanecarboxylate (SMCC); N—sulfosuccinimidyl 4-(maleimidomethyl)
cyclohexanecarboxylate (sulfoSMCC); N—succinimidyl(iodoacetyl)-aminobenzoate
(SIAB); and N—succinimidyl—[(N-maleimidopropionamido)—tetraethyleneglycol] ester
(NHS-PEG4-maleimide). In another embodiment, the linker is N—succinimidyl 4-(2-
pyridyldithio)-2—sulfobutanoate (sulfo-SPDB). In r embodiment, the cytotoxic agent
is selected from the group consisting of a maytansinoid, maytansinoid analog,
benzodiazepine, taxoid, CC—1065, CC-1065 analog, mycin, duocarmycin analog,
calicheamicin, dolastatin, dolastatin analog, auristatin, tomaymycin derivative, and
leptomycin derivative or a prodrug of the agent. In another embodiment, the cytotoxic
agent is a maytansinoid. In another embodiment, the cytotoxic agent is N(2')-deacetyl-
N(2')—(3 -mercapto- 1 opyl)-maytansine or deacetyl-NZ-(4-mercapto—4-methyl— l -
oxopentyl)—maytansine. In another embodiment, the xic agent is N(2')-deacetyl-N2—
(4-mercaptomethyl-l-oxopentyl)—maytansine (DM4). In a further ment, the
immunoconjugate comprises the antibody HUMOV19, sulfo-SPDB, and DM4 (IMGN853).
The invention is also directed to a kit for measuring FOLRI expression in a subject
comprising a FOLRl detection reagent, and instructions for use. In one embodiment, the
FOLRl detection reagent comprises a FOLRl binding peptide, protein or a molecular probe
(i.e. nucleic acid). In another embodiment, the FOLRl detection reagent is an anti-FOLRI
antibody. In another embodiment, the kit r ses a ary antibody which
binds the anti-FOLRl dy. In one embodiment the antibody is included at a
concentration of 0.5 to 7.5 ug/ml, desirably 0.9 to 3.8 +/- 0.5 ug/ml. In various
embodiments, the antibody is included at a concentration of 1.0 +/— 0.5 ug/ml, 1.5 +/— 0.5
ug/ml, 1.9 +/- 0.5 ug/ml, 2.5 +/— 0.5 ug/ml, 3.0 +/- 0.5 ug/ml, 3.5 +/- 0.5 pig/ml, 3.8 +/- 0.5
ug/ml, or up to 4.2 ug/ml. In another embodiment, the antibody is ed in concentrated
solution with instructions for ons to achieve a final concentration of 0.9 to 3.8 +/— 0.5
rig/ml. In another embodiment, the kit further comprises a detection reagent selected from
the group consisting of: an enzyme, a fluorophore, a radioactive label, and a luminophore.
In another embodiment, the detection reagent is selected from the group consisting of:
biotin, digo-xigenin, fluorescein, tritium, and ine.
The kit can also include instructions for detection and scoring of FOLRl expression.
The kit can also e control or reference samples. Non-limiting examples of control or
reference samples include tissue samples, cell pellets or cells. The controi or reference
samples may be derived from tissue culture cell lines (normal or tumor), normal tissue
(normal control) or tumor tissues (positive control) samples. Exemplary cell lines include
SW620, T47D, IGROV-l, HELA, KB, JEG-3 and cell lines stably or ently transfected
with an expression vector that expresses FOLRl (e.g., 300.19FR1). Exemplary tissues that
detection methods are
may be used as normal reference tissues in the FOLRl expression
described herein and include normal lung, salivary gland, and pancreas.
The invention is also directed to a method for identifying a cancer likely to respond
to an anti-FOLRl antibody, or anti-FOLRl immunoconjugate comprising: (a) contacting a
biological sample comprising cells from said cancer with an agent that binds FOLRl protein
on the cell surface; (b)detecting g of said agent that binds FOLRl n on the cell
surface of said biological sample of (a); (c) assigning a score to said binding of step (b),
wherein said score is assigned based on ison to one or more reference samples; and
(d) comparing said score in step (c) to the score of a reference tissue or cell, wherein a score
for said cancer FOLRl level that is greater than the score for a normal or low P‘O'LRI
sing reference sample or a score for said cancer FOLRl level that is equal to or
greater than the score for a high FOLRl expressing reference sample fies said cancer
as likely to respond to an anti—FOLRI antibody or anti-FOLRl immunoconjugate. In
certain embodiments, the cancer is ovarian or lung cancer.
The invention is also ed to a method of identifying a tumor as sensitive to
treatment with an anti-FOLRI antibody, or anti—FOLRI immunoconjugate, said method
comprising: (a) measuring the level of FOLRI expression in a tumor tissue sample obtained
from said tumor, wherein said ing comprises the use of a detection method that
guishes between staining intensity or staining uniformity in a FOLRI expressing
cancer sample as compared to staining intensity or staining uniformity in one or more
reference samples; (b) determining a FOLRI staining intensity score for said tumor tissue
; and (c) ing the FOLRI ng intensity score determined in step (b) to a
relative value determined by measuring FOLRI protein expression in at least one nce
sample, wherein said at least one reference sample is a tissue, cell, or cell pellet sample
which is not sensitive to treatment with an anti—FOLRI antibody, or anti-FOLRl
immunoconjugate, and wherein a FOLRI staining intensity score for said sample
determined in step (b) that is higher than said relative value identifies said tumor as being
sensitive to treatment with an anti—FOLRl dy, or anti—FOLRI immunoconjugate. In
certain embodiments, the detection method is performed manually or using an automated
system. In one embodiment, the detection method is IHC. In another embodiment, the IHC
is calibrated IHC that can distinguish different levels of FOLRl expression.
The invention is also directed to a method of optimizing a therapeutic regimen with
an anti-FOLRI dy or an anti-FOLRI immunoconjugate for a subject having lung or
ovarian cancer, said method comprising: (a) contacting said sample from said subject with
an antibody that specifically binds cell surface FOLRI; (b) éng the binding of said
antibody in (a) to said cell surface FOLRl in said sample using a detection method that can
distinguish between staining intensity or staining uniformity in a FOLRI expressing cancer
sample as compared to staining intensity or staining uniformity in one or more reference
samples and assigning a staining score to said sample; and (c) administering a high dose of
an anti-FOLRl immunoconjugate when the score in step (b) is less than or equal to the
score for a normal or low FOLRl expressing reference sample or administering a low dose
of an anti—FOLRI immunoconjugate when the score is r than the score for a normal or
low FOLRl expressing reference sample.
The ion is also directed to a method of detecting the expression of cell surface
FOLRl on cancer cells in a tumor tissue sample from a subject, said method comprising: (a)
obtaining tumor tissue sample, wherein said cancer sample is formalin-fixed paraffin
embedded; (b) ting said sample with an antibody that cally binds cell surface
FOLR1; (c) measuring the binding of said antibody in (b) to said cell surface FOLR1
in said tumor tissue sample using a detection method that can distinguish between
staining intensity or staining uniformity in a FOLR1 expressing cancer sample as
compared to staining intensity or staining uniformity in one or more reference
samples; and (d) assigning a FOLR1 expression score to said FOLR1 after comparing
the level of cell surface FOLR1 staining intensity or staining uniformity in said tumor
tissue sample to one or more reference samples.
The invention is also directed to a method of identifying a subject having a
lung or ovarian cancer as likely to respond to a low dose anti-FOLR1 antibody or
anti-FOLR1 immunoconjugate treatment regimen, said method comprising: (a)
contacting a biological sample comprising cells from said n or lung cancer with
an agent that binds cell surface FOLR1 protein; (b) detecting binding of said agent to
said ical sample of (a); (c) assigning a score to said binding of step (b),
wherein said score is assigned based on comparison to one or more reference samples;
and (d) comparing said score in step (c) to the score of a reference tissue or cell,
n a score for said ovarian or lung cancer FOLR1 level that is greater than the
score for a normal or low FOLR1 expressing reference sample or a score for said
ovarian or lung cancer FOLR1 level that is equal to or greater than the score for a
high FOLR1 expressing reference sample identifies said ovarian or lung cancer as
likely to d to a low dose anti-FOLR1 antibody or anti-FOLR1
conjugate. In certain embodiments, the method further comprises
stering a therapeutically ive amount of a zed anti-FOLR1
antibody or an anti-FOLR1 conjugate to said subject.
[0023a] Definitions of the specific embodiments of the ion as claimed herein
follow.
[0023b] According to a first embodiment of the ion, there is provided a method
of identifying a tumor as sensitive to treatment with an anti-Folate Receptor 1
(FOLR1) antibody or antigen binding fragment thereof, the method comprising:
(a) measuring the level of FOLR1 expression in a tumor tissue sample
obtained from the tumor, wherein the measuring comprises the use of a detection
method that distinguishes between ng intensity and ng uniformity in a
FOLR1-expressing cancer sample as compared to staining intensity and staining
uniformity in one or more reference samples;
(b) determining a FOLR1 staining intensity score for the tumor tissue
sample; and
(c) comparing the FOLR1 staining intensity score determined in step (b) to
a reference value determined by measuring FOLR1 protein expression in at least one
reference sample, wherein the at least one reference sample is a , cell, or cell
pellet sample which is not sensitive to treatment with an anti-FOLR1 antibody or
antigen binding fragment f, wherein a FOLR1 staining ity score for the
tumor tissue sample ined in step (b) that is higher than the reference value
identifies the tumor as being sensitive to treatment with an anti-FOLR1 antibody or
n binding fragment thereof, and wherein the anti-FOLR1 antibody or antigen
binding fragment thereof for treatment comprises (i) a heavy chain (HC) CDR1
comprising the amino acid sequence GYFMN (SEQ ID NO:6); a HC CDR2
comprising the amino acid sequence RIHPYDGDTFYNQKFQG (SEQ ID NO:7); and
a HC CDR3 comprising the amino acid sequence YDGSRAMDY (SEQ ID NO:8)
and (ii) a light chain (LC) CDR1 comprising the amino acid sequence
KASQSVSFAGTSLMH (SEQ ID NO:9); a LC CDR2 comprising the amino acid
sequence RASNLEA (SEQ ID NO:10); and a LC CDR3 comprising the amino acid
sequence QQSREYPYT (SEQ ID NO:11).
[0023c] ing to a second embodiment of the invention, there is provided a
method of identifying a tumor as sensitive to treatment with an anti-FOLR1
immunoconjugate, the method comprising:
(a) measuring the level of FOLR1 sion in a tumor tissue sample
obtained from the tumor, wherein the measuring comprises the use of a detection
method that distinguishes between staining intensity and staining mity in a
FOLR1 expressing cancer sample as compared to staining ity and staining
uniformity in one or more reference samples;
(b) ining a FOLR1 staining intensity score for the tumor tissue
sample; and
(c) comparing the FOLR1 staining intensity score determined in step (b) to
a nce value determined by measuring FOLR1 protein expression in at least one
reference sample, wherein the at least one reference sample is a tissue, cell, or cell
pellet sample which is not sensitive to treatment with an anti-FOLR1
immunoconjugate, wherein a FOLR1 staining intensity score for the tumor tissue
sample determined in step (b) that is higher than the reference value identifies the
tumor as being sensitive to treatment with an anti-FOLR1 immunoconjugate, wherein
the anti-FOLR1 immunoconjugate for treatment has the formula (A) – (L) – (C),
wherein:
(A) comprises an anti-FOLR1 antibody or antigen binding fragment
thereof sing (i) a HC CDR1 comprising the amino acid sequence GYFMN
(SEQ ID NO:6); a HC CDR2 comprising the amino acid sequence
RIHPYDGDTFYNQKFQG (SEQ ID NO:7); and a HC CDR3 comprising the amino
acid sequence MDY (SEQ ID NO:8) and (ii) a LC CDR1 comprising the
amino acid sequence KASQSVSFAGTSLMH (SEQ ID NO:9); a LC CDR2
comprising the amino acid sequence RASNLEA (SEQ ID NO:10); and a LC CDR3
comprising the amino acid sequence QQSREYPYT (SEQ ID NO:11), (L) comprises a
linker, (C) comprises a cytotoxic agent, and wherein (L) links (A) to (C).
BRIEF DESCRIPTIONS OF THE DRAWINGS
Figure 1. Manual ng Method: Anti -FOLR1 antibodies detect FOLR1
sion in transfected cells. 300.19 cells were transfected with a polynucleotide
that encodes human FOLR1. FOLR1 n expression was detected using the
murine antibody BN3.2. Smith AE et al, Hybridoma (Larchmt). 2007 Oct;26(5):281 -
Figure 2. Manual Staining Method: Anti-FOLR1 dies can distinguish
different levels of FOLR1 expression. Antibody BN3.2 was used to detect FOLR1
expression in various xenograft cells. The limit of detection for the BN3.2 dy
was approximately 4000 antibodies bound per cell (ABC).
[TEXT CONTINUES ON PAGE 8]
Figure 3. Manual Staining Method: Anti-FOLRl antibodies can distinguish
different levels of FOLRI expression in tissue samples. BN3.2 was used to detect FOLRl
expression in both ovarian tumors (A), as well as non-small cell lung cancer tumors (B).
Figure 4. Manual Staining Method: Uniform FOLRl expression in ovarian and
NSCLC tumors. FOLRl expression was high in many of the ovaréan carcinomas, as well as
lung adenocarcinomas and bronchioloalveolar carcinomas tested. The ty of n
carcinoma samples had the highest intensity staining in serous or endometrioid cells. In the
NSCLC tumors, the highest ABC values were found in bronchioloalveolar carcinoma and
papillary adenocarcinoma.
Figure 5. Manual Staining Method: FOLRl expression is generally confined to the
membrane of NSCLC cells. High resolution copy revealed that the majority of
FOLRl staining was restricted to the membrane in NSCLC tumors.
Figure 6. Manual Staining Method: FOLRl expression is lly d to the
membrane of ovarian cancer cells. High resolution microscopy revealed that the majority of
FOLRl staining was restricted to the ne in ovarian tumors.
Figure 7. In vivo efficacy of huMovl9-targeted conjugates in a KB xenograft
model. FOLRl-targeting cleavable conjugate huMovl9-SPDB—DM4 (B) in comparison
with non-FOLRl—targeting huC242-SPDB-DM4 (D), and eavable conjugate
huMovl9-PEG4-Mal-DM4 (C) in comparison with non-targeting huC242-PEG4Mal-DM4
(B) were tested using an established xenograft model of KB cells implanted subcutaneous
into SCID mice. Targeting of FOLRl by huMov19 resulted in significant ion in
mean tumor volume.
Figure 8. Dose-response anti-tumor activity of IMGN853 treatment in OVCAR—3
human ovarian carcinoma xenografts. Mice were treated with a single intravenous ion
of 3 at 1.2, 2.5 or 5.0 mg/kg. A control group of animals received a single
intravenous injection of PBS.
Figure 9. Dose—response umor ty of IMGN853 treatment in lGROV—l
human ovarian carcinoma xenografts. Mice were treated with a single intravenous injection
of IMGN853 at 1.2, 2.5 or 5.0 mg/kg. A control group of animals received a single
intravenous injection of PBS.
Figure 10. Dose-response anti-tumor activity of IMGN853 treatment in OV-90
human ovarian carcinoma xenografts. Mice were treated with a single intravenous injection
of IMGN853 at 1.2, 2.5 or 5.0 mg/kg. A control group of animals received a single
intravenous injection of PBS.
Figure 11. Dose-response anti—tumor ty of 3 treatment in SKOV—3
human ovarian carcinoma xenografts. Mice were treated with a single enous injection
of 3 at 1.2, 2.5 or 5.0 mg/kg. A control group of animals received a single
intravenous injection of PBS.
Figure 12. Dose-response anti-tumor activity of IMGN853 treatment in KB human
cervical adenocarcinoma xenografts. Mice were treated with a single intravenous injection
of IMGN853 at 1.0, 2.5 or 5.0 mg/kg. A control group of s received a single
intravenous injection of PBS.
Figure 13. Automated Staining Methods: Representative Photographs and
Histograms depicting FOLRl Expression in Cell Lines by IHC and Flow Cytometry.
SW620, T47D, Igrov-l, 300.19/FR1, HeLa, and KB cells were all scored for FOLRl
staining intensity and uniformity. SWti30 and IGROV-l cells were scored 1—3 hetero,
T47D was scored 1-2 hetero, HeLa was scored 2-3 hetero, while 300.19/FR1 and KB were
scored 3 homo.
Figure 14. Automated Staining Methods: Representative FOLR] Staining in Serous
Ovarian Cancer. Staining patterns demonstrating 3 homo, 2-3 homo, 2 homo, and 2 hetero
staining are shown for tissue ns from serous ovarian cancer by IHC.
[0038} Figure 15. Automated Staining Methods: Representative FOLRl Staining in
Endometrioid Ovarian Cancer. Staining patterns demonstrating 3 homo, 2—3 homo, 3 focal,
and 1-2 hetero staining are shown for tissue sections from endometroid cancer by IHC.
Figure 16. Automated Staining Methods: entative FOLRl Staining in
NSCLC of the arcinoma Subtype (excluding ioloalveolar carcinomas).
Staining patterns demonstrating 3 homo, 2-3 homo, 2 hetero, 2 homo, and 1-2 hetero
staining are shown for tissue sections from non-small cell lung cancer, adenocarcinoma
subtype by IHC.
{0040} Figure 17. Automated Staining Methods: Representative FOLRl Staining in
trial Adenocarcinoma. Staining patterns demonstrating 3 hetero, 2 hetero, and 1
hetero staining are shown for tissue sections from endometrial adenocarcinoma by IHC.
{0041} Figure 18. Automated Staining Methods: Representative FOLRl Staining in Renal
Clear Cell Carcinoma. Staining patterns demonstrating 2 homo, 2 hetero, and l heteto
staining are shown for tissue sections from renal cell cancer by IHC.
tests; Figure 19. The cytotoxic aetivity of iMGNSiiB in vitro. Five Fifiil‘fiwpositive eeli
lines (KB? iGROV—l, IE i~3, SKOVG and OVCAR.~3} and two FOLRiwnegative cell, tines
iwa and SW2) were analyzed for their sensitivity to the cytotoxic effects of
liviGN8530 Cells were d to il‘VKiNSSB {solid line) or to lMGNtiSB plus 0.5 nM
unconingated iinMo'Vl9 (M9346A) (dashed iine) for 5 days, and the eeil survival was
determined by WSlmg-based assay, Representative data are shown, The percent of surviving
eelis was d t base it} iogaritlnn Of'ii‘itj concentration of EMGN853.
rests} Figure 20. The sensitivity of‘tlie linQRl-positive cell lines to EMGNXSB versus the
level of itiOLRi expression. Potency and specificity of EMGN853 was anaiyzed against
FGLRl—positive cell lines with a wide range of FOLRl expression. Cell lines were
incubated Win lMGN853 and KB, igi'oV—L and 3eg~3 were sneeifieaily sensitive to
iMGNts‘Sfi While unconjugated huMoVIS} (M9346A) snowed decreased activity of the
ate. Skew—3 and ()V‘earfi were not sensitiVe to EMGNSSS and unconjugaled
huMovl?) A) did not change the activity of the conjugate.
gss4t; Figure 21. Automated Staining Methods: n Carcinoma Xenograft etiieaey
models stained for FOLRl. ng patients trating 1:3 hetero (Swat '3), i—3 homo
(lgrov i), l~2 hetero (CV 90) and negative (SKOV 3:) are shown for tissue sections from
ovarian cancer xenografts by Eli—1C.
insist Figure ‘22. Automated Staining Methods: Mouse Xenograft Modeisi ng
patterns for FOLRl in xei'iograi‘ts for NSCLC (A), Entionietriuni Carcinoma (B) and
Cervical Carcinoma (C) Ceil Lines are shown. NSCLC samples demonstrated 23 homo or
2 homo staining, endometrinni oma demonstrated 2 hetero/3 focal staining, and
cervical carcinoma demonstrated 3 homo staining.
tests} ,li'ig‘are 23. Assay control tissues automated staining guide. Staining patterns for
negative (esophagus ti} and positive control samples (salivary gland L2 hetero? lung 21
homo, pancreas 3 home) are shown as determined by automated EHC.
{9347; Figure- 34. Tumor tissues automated staining guide. Representative staining patterns
for ievei 3,, {eve}. 2, and level i ng are shown on control tissue as detennined by
automated iii-iii.
{sets} Figure 25. Turner tissues automated staining guide, Representative ng
patterns for level 3?, level, 2, and Eevei l/negative staining are shown. on control tissue as
determined by automated ii-lC.
DETAILED DESCRIPTION OF THE INVENTION
{00419} The present inventien presides methods for increasing the efficacy of er the
hood of response to the treatment of cancers characterised by the everexpressien of
FOLRI. The present invention is based on the discovery of a dynamic range of expression
of FOLRE in tumor tissue as compared to nerrnai tissue and the discovery that tumors with
sed. Eevels nf FOLK} expression are more sive te treatment with anti—FOLK}
antibodies or ‘OlgRi irnmunoconjugate *, We have else discovered differences in
sensitity and detection of c ranges between ated and manual methods. Kits
comprising one or more reagents useful fer practicing the methods of the invention are
further provided
1. Definitions
To facilitate an understanding of the present invention, a number of terms and
phrases are defined below.
{0051} The terms "human folate receptor 1" or "FOLRI", as used herein, refers to any
native human FOLRI, unless otherwise indicated. The term "FOLRI" encompasses "full-
length," unprocessed FOLR] as well as any form of FOLRl that results from processing
within the cell. The term also asses naturally occurring variants of FOLRl, e.g.,
splice variants, allelic ts and ms. The FOLRI polypeptides described herein can
be isolated from a variety of sources, such as from human tissue types or from another
source, or prepared by recombinant or synthetic methods. Examples of FOLRI sequences
include, but are not limited to NCBI reference s P15328, NP_001092242.1,
AAX292681, AAXBH 19.}, Ni§>g057937.l, and NP_O57936.1, and those shown in SEQ iii)
NOS: 1 and 2.
The term “increased expression" of FOLRI refers to a sample which contains
elevated levels of FOLRl expression. In one example, the FOLRI expression is measured
by IHC and given a staining intensity score or a staining uniformity score by comparison to
controls (e.g., ated controls) exhibiting defined scores (e.g. an intensity score of 3 is
given to the test sample if the intensity is comparable to the level 3 calibrated l or an
intensity of 2 is given to the test sample if the intensity is comparable to the level 2
calibrated control). For example, a score of 1, 2, 3, or 3+ or greater by
immunohistochemistry indicates an increased expression of FOLRI. A staining uniformity
that is heterogeneous or homogeneous is also indicative of increased FOLRI expression.
“11.,
The staining iretensity and ng uniformity scores can be used alone or in combination
(e.g., 2 homo, 2 hetero, 3 homo, 3 hetero, etc.). In another example, an increase in FOLRI
sion can be determined by detection of an increase of at least 2-fold, at least 3-fold, or
at least 5-fold) relative to control values (e.g., expression level in a tissue or cell from a
subject without cancer or with a cancer that does not have elevated FOLRI ).
A "reference sample" can be used to correlate and compare the results ed in
the methods of the invention from a test sample. Reference samples can be cells (e.g., cell
lines, cell pellets) or tissue. The FOLRl levels in the "reference sample" may be an
absolute or relative amount, a range of amount, a minimum and/or maximum amount, a
mean amount, and/or a median amount of FOLRI. The diagnostic methods of the invention
involve a comparison between expression levels of FOLRI in a test sample and a "reference
value." In some embodiments, the reference value is the expression level of the FOLRl in a
reference sample. A reference value may be a predetermined value and may also be
determined from reference samples (e.g., control biological samples) tested in parallel with
the test samples. A nce value can be a single cut—off value, such as a median or mean
or a range of , such as a confidence interval. Reference values can be established for
various subgroups of duals, such as individuals predisposed to cancer, individuals
having early or late stage cancer, male and/or female individuals, or individuals oing
cancer therapy. Examples of normal reference samples or values and positive reference
samples or values are described herein.
In some embodiments, the reference sample is a sample from a healthy tissue, in
ular a corresponding tissue which is not affected by cancer. These types of reference
samples are referred to as ve control samples. In other embodiments, the nce
sample is a sample from a tumor tissue that expresses FOLRl. These types of reference
samples are referred to as positive control samples. Positivie control samples can also be
used as a comparative indicator for the uniformity (hetero versus homo) and/or degree (1, 2,
3, 3+) of ng ity, which correlates with the level of FOLRl expression. Positive
control comparative samples are also referred to as calibrated reference samples which
demonstrate a dynamic range of staining intensity or uniformity. As shown in Examples 1-
9, non FOLRl-expressing reference samples include human esophagus tissue; low FOLRI
nce includes salivary gland (particularly the intercalated ducts) and lung (particularly
respiratory epithelium) tissue; and high expressing tissue includes the pancreas
cularly ductal cells). For cell lines, low expressors include, but are not limited to
-12...
OVCAR3 and T471), moderate expressers include, but are not limited in SW‘tSZi), i lRUX/ll,
515.63, and high expressers include, but are not d to, KB and EGROVE. Particularly
desirable positive high FOLK} nce is a cell line stably or transiently transt‘eeted with
Folate Receptor 1 (e.g., 300.19/FR1). Appropriate positive and negative reference levels of
FOLRl for a particular cancer, may be determined by measuring levels of FOLRl in one or
more appropriate subjects, and such reference levels may be tailored to specific populations
of subjects (e.g., a reference level may be age-matched so that comparisons may be made
between FOLRl levels in samples from subjects of a certain age and reference levels for a
particular disease state, phenotype, or lack thereof in a n age . Such reference
levels may also be tailored to specific techniques that are used to measure levels of FOLRl
in biological samples (e.g., immunoassays, etc.), where the levels of FOLRl may differ
based on the specific technique that is used.
The term "primary antibody" herein refers to an antibody that binds specifically to
the target protein antigen in a tissue sample. A primary antibody is lly the first
dy used in an histochemical (IHC) procedure. In one embodiment, the
primary antibody is the only antibody used in an IHC procedure. The term "secondary
antibody" herein refers to an antibody that binds specifically to a primary antibody, thereby
forming a bridge n the primary antibody and a uent reagent, if any. The
secondary antibody is generally the second antibody used in an immunohistochemical
procedure.
{9956} A "sample" or "biological sample" of the present invention is of biological origin, in
specific embodiments, such as from eukaryotic organisms. In preferred embodiments, the
sample is a human sample, but animal samples may also be used in the practice of the
invention. Non-limiting sources of a sample for use in the present invention include solid
tissue, biopsy aspirates, ascites, fluidic extracts, blood, plasma, serum, spinal fluid, lymph
fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears,
saliva, milk, , organs, cell cultures and/or cell e constituents, for example. The
present invention is particularly useful for cancer samples which generally se solid
tissue samples, or other bodily fluids such as ascites, where the amount of available material
is small. The method can be used to examine an aspect of expression of FOLRl or a state of
a sample, including, but not d to, comparing different types of cells or tissues,
ing different pmental , and detecting or determining the presence and/or
type of disease or abnormality.
For the purposes herein, a "section" of a tissue sample refers to a single part or piece
of a tissue sample, e.g. a thin slice of tissue or cells cut from a tissue sample. It is
understood that multiple sections of tissue samples may be taken and subjected to analysis
according to the present invention. In some cases, the selected portion or section of tissue
comprises a homogeneous population of cells. In other cases, the selected portion comprises
a region of tissue, e.g. the lumen as a non-limiting example. The ed n can be
small as one cell or two cells, or could represent néany thousands of cells, for example. In
most cases, the collection of cells is important, and while the ion has been bed
for use in the detection of cellular components, the method may also be used for detecting
non-cellular components of an sm (e.g. soluble components in the blood as a non—
limiting example).
{0058] By "correlate" or "correlating" is meant comparing, in any way, the performance
and/0r results of a first analysis with the performance and/or results of a second analysis.
For example, one may use the results of a first analysis in carrying out the second analysis
and/or one may use the results of a first analysis to determine whether a second analysis
should be performed and/or one may compare the results of a first analysis with the results
of a second analysis. In one embodiment, increased expression of FOLRl correlates with
increased likelihood of effectiveness of a FOLRl-targeting anti-cancer therapy.
FREQ} The term "antibody" means an immunoglobulin molecule that izes and
specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate,
polynucleotide, lipid, or combinations of the foregoing through at least one antigen
recognition site Wéthin the le region of the immunoglobulin molecule. As used
herein, the term “antibody” encompasses intact polyclonal antibodies, intact monoclonal
dies, antibody fragments (such as Fab, Fab', F(ab')2, and Fv fragments), single chain
Fv (scFv) mutants, multispecific antibodies such as bispecific antibodies generated from at
least two intact antibodies, chimeric antibodies, humanized dies, human dies,
fusion proteins sing an antigen determination portion of an antibody, and any other
modified immunoglobulin molecule comprising an antigen recognition site so long as the
antibodies exhibit the d biological activity. An antibody can be of any the five major
classes of immunoglobulins: EgA, IgD, IgE, IgG, and IgM, or sses (isotypes) thereof
(e.g. IgGl, lgGZ, IgG3, lgG4, IgAl and IgA2), based on the identity of their heavy-chain
constant domains ed to as alpha, delta, epsilon, gamma, and mu, resFectively. The
different s of immunoglobulins have different and well known subunit structures and
three~dimensional configurations. Antibodies can be naked or conjugated to other
molecules such as toxins, radioisotopes, etc.
{0060} A ing" antibody or an "antagonist" antibody is one which inhibits or reduces
biological activity of the antigen it binds, such as FOLRl. In a certain ment blocking
dies or antagonist antibodies substantially or tely t the biological activity
of the antigen. bly, the biological activity is reduced by 10%, 20%, 30%, 50%, 70%,
80%, 90%, 95%, or even 100%.
{006;} The term "anti-FOLRI antibody" or "an antibody that binds to FOLRl" refers to an
antibody that is capable of binding FOLRl with ent affinity such that the antibody is
useful as a diagnostic and/or therapeutic agent in targeting FOLRl. The extent of binding of
an anti-FOLRl antibody to an unrelated, non—FOLRl protein is less than about 10% of
binding of the antibody to FOLRl as measured, e.g., by a radioimmunoassay (RIA). In
certain embodiments, an antibody that binds to FOLRl has a dissociation constant (Kd) of
:1 nM, 5100 nM, 510 nM, 51 nM, or 50.1 nM. Examples of anti-FOLRI antibodies are
known in the art and are disclosed in US Appl. Pub. No. 2012/0009181, which is herein
incorporated by reference.
The term "antibody fragment" refers to a portion of an intact antibody and refers to
the antigenic determining variable regions of an intact antibody. Examples of antibody
fragments include, but are not limited to Fab, Fab', 2, and Fv fragments, linear
antibodies, single chain antibodies, and multispecifrc dies formed from antibody
fragments.
{0063] A "monoclonal antibody" refers to a homogeneous antibody population involved in
the highly specific recognition and binding of a single antigenic inant, or epitope.
This is in contrast to polyclonal antibodies that typically e different antibodies
directed against different antigenic determinants. The term lonal antibody”
encompasses both intact and ength monoclonal dies as well as antibody
fragments (such as Fab, Fab', F(ab')2, Fv), single chain (scFv) mutants, fusion proteins
comprising an antibody portion, and any other modified immunoglobulin molecule
comprising an n recognition site. Furthermore, ”monoclonal antibody" refers to such
antibodies made in any number of manners including but not limited to by hybridoma,
phage selection, recombinant expression, and transgenic animals.
{90%} The term "epitope" or "antigenic determinant" are used interchangeably herein and
refer to that portion of an antigen capable of being recognized and specifically bound by a
particular antibody. When the n is a polypeptide, epitopes can be formed both from
contiguous amino acids and noncontiguous amino acids juxtaposed by tertiary folding of a
protein. Epitopes formed from contiguous amino acids are typically retained upon protein
denaturing, s epitopes formed by tertiary folding are typically lost upon protein
denaturing. An epitope lly es at least 3, and more usually, at least 5 or 8-10
amino acids in a unique spatial conformation.
"Binding affinity" generally refers to the strength of the sum total of noncovalent
interactions between a single binding site of a moiecule (e.g., an dy) and its binding
partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity"
refers to sic binding affinity which reflects a 1:1 interaction between members of a
binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can
generally be represented by the dissociation constant (Kd). Affinity can be measured by
common methods known in the art, including those described herein. Low-affinity
antibodies generally bind antigen slowly and tend to dissociate readily, whereas high—
affinity antibodies generally bind antigen faster and tend to remain bound longer. A varéety
of s of measuring g affinity are known in the art, any of which can be used for
purposes of the present invention. Specific illustrative embodiments are described in the
following.
"Or better" when used herein to refer to binding affinity refers to a stronger binding
between a molecule and its binding partner. "Or better" when used herein refers to a
stronger binding, represented by a smaller numerical Kd value. For example, an antibody
which has an y for an n of "0.6 nM or better", the dy’s affinity for the
antigen is <0.6 nM, i.e. 0.59 nM, 0.58 nM, 0.57 nM etc. or any value less than 0.6 nM.
The phrase "substantially similar," or "substantially the same", as used herein,
denotes a sufficiently high degree of similarity between two numeric values (generally one
associated with an antibody of the invention and the other associated with a
reference/comparator antibody) such that one of skill in the art would consider the
difference n the two values to be of little or no biological and/or tical
significance within the context of the biological characteristics measured by said values
(e.g., Kd values). The difference between said two values is less than about 50%, less than
about 40%, less than about 30%, less than about 20%, or less than about 10% as a function
of the value for the reference/comparator antibody.
»
{006813 A polypeptide, antibody, polynucleotide, , cell, or composition which is
"isolated" is a polypeptide, antibody, polynucleotide, vector, cell, or composition which is
in a form not found in . isolated polypeptides, antibodies, polynucleotides, vectors,
cell or compositions include those which have been purified to a degree that they are no
longer in a form in which they are found in nature. In some embodiments, an antibody,
polyaucleotide, vector, cell, or composition which is isolated is substantially pure.
As used herein, "substantially pure" refers to material which is at least 50% pure
(i.e., free from contaminants), at least 90% pure, at least 95% pure, at least 98% pure, or at
least 99% pure.
The term "immunoconjugate" or "conjugate" as used herein refers to a compound or
a derivative thereof that is linked to a cell g agent (i.e., an anti-FOLRl antibody or
fragment thereof) and is defined by a generic a: C-L-A, wherein C = cytotoxin, L =
linker, and A — cell binding agent or anti-FOLRl antibody or antibody nt.
lmmunoconjugates can also be defined by the generic formula in reverse order: A-L-C.
[0%71] A "linker" is any chemical moiety that is capable of linking a compound, usually a
drug, such as a maytansinoid, to a cell-binding agent such as an anti FOLRI antibody or a
fragment thereof in a stable, covalent . Linkers can be tible to or be
ntially resistant to nduced cleavage, light-induced cleavage, peptidase-induced
cleavage, esterase-induced cleavage, and disulfide bond cleavage, at conditions under which
the compound or the antibody remains active. Suitable linkers are well known in the art and
include, for example, disulfide groups, thioether groups, acid labile groups, photolabile
groups, peptidase labile groups and esterase labile groups. Linkers also include charged
linkers, and hydrophilic forms thereof as described herein and know in the art.
The terms "cancer" and "cancerous" refer to or describe the physiological condition
in mammals in which a population of cells are characterized by unregulated cell growth.
Examples of cancer e, but are not limited to, oma, lymphoma, blastoma,
sarcoma, and leukemia. More particular examples of such cancers include squamous cell
cancer, small-cell lung cancer, non—small cell lung cancer, adenocarcinoma of the lung,
squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer,
gastrointestinal cancer, pancreatic , glioblastoma, cervical cancer, n cancer,
liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal ,
endometrial or e carcinoma, salivary gland carcinoma, kidney cancer, liver cancer,
prostate , vulval cancer, thyroid cancer, hepatic carcinoma and various types of head
and neck cancers.
{0073] "Tumor" and "neoplasm" refer to any mass of tissue that result from excessive cell
growth or proliferation, either benign (noncancerous) or malignant (cancerous) including
pre—cancerous lesions.
The terms "cancer cell," "tumor cell," and grammatical equivalents refer to the total
population of cells deréved from a tumor or a pre—cancerous lesion, including both nontumorigenic
cells, which comprise the bulk of the tumor cell tion, and tumorigenic
stem cells (cancer stem cells). As used herein, the term “tumor cell” will be modified by the
term “non—tumorigenic” when referring solely to those tumor cells lacking the capacity to
renew and differentiate to distinguish those tumor cells from cancer stem cells.
The term "subject" refers to any animal (e. g., a mammal), including, but not limited
to humans, non-human primates, rodents, and the like, which is to be the recipient of a
particular treatment. Typically, the terms ct" and "patient" are used interchangeably
herein in reference to a human subject.
stration "in combination with" one or more further therapeutic agents
includes simultaneous (concurrent) and consecutive administration in any order.
The term "pharmaceutical formulation" refers to a preparation which is in such form
as to permit the biological activity of the active ingredient to be effective, and which
ns no additional components which are unacceptably toxic to a subject to which the
formulation would be administered. Such formulation can be sterile.
An "effective amount" of an dy as disclosed herein is an amount sufficient to
carry out a specifically stated purpose. An "effective amoun can be determined
empirically and in a routine , in relation to the stated purpose.
The term "therapeutically effective " refers to an amount of an antibody or
other drug effective to "treat" a disease or disorder in a t or mammal. In the case of
cancer, the therapeutically effective amount of the drug can reduce the number of cancer
cells; reduce the tumor size; inhibit (i.e., slow to some extent and in a certain embodiment,
stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and in a
certain embodiment, stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or
relieve to some extent one or more of the symptoms associated with the cancer. See the
definition herein of ing". To the extent the drug can prevent growth and/or kill ng
cancer cells, it can be cytostatic and/or cytotoxic. In n ments, identification of
-18<—
increased FOLRl levels allows for administration of sed amounts of the FOLRl-
targeting therapeutic to achieve the same therapeutic effect as seen with higher dosages. A
"prophylactically effective amount" refers to an amount effective, at dosages and for s
of time necessary, to achieve the desired prophylactic result. Typically but not arély,
since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the
prophylactically effective amount will be less than the therapeutically effective amount.
The term "respond favorably" generally refers to causing a beneficial state in a
subject. With respect to cancer treatment, the term refers to providing a therapeutic effect
on the subject. Positive therapeutic effects in cancer can be measured in a number of ways
(See, W.A. Weber, J. Nucl. Med. 50:lS-IOS (2009)). For example, tumor growth
inhibition, molecular marker sion, serum marker expression, and molecular imaging
techniques can all be used to assess therapeutic y of an anti—cancer therapeutic. With
to tumor growth inhibition, according to NCI standards, a T/C S 42% is the
respect
minimum level of anti-tumor activity. A T/C <10% is considered a high anti—tumor activity
level, with T/C (%) = Median tumor volume of the d / Median tumor volume of the
control x 100.
The word "label" when used herein refers to a detectable nd or composition
which is conjugated directly or indirectly to the antibody so as to generate a "labeled"
antibody. The label can be able by itself (e.g. radioisotope labels or fluorescent labels)
or, in the case of an enzymatic label, can catalyze al alteration of a substrate
compound or composition which is detectable.
A "chemotherapeutic agent" is a chemical compound useful in the treatment of
cancer, regardless of mechanism of action. Classes of chemotherapeutic agents include,
are not limited to: alkyating agents, antimetabolites, spindle poison plant alkaloids,
cytoxic/antitumor antibiotics, omerase inhibitors, dies, photosensitizers, and
kinase tors. Chemotherapeutic agents include compounds used in "targeted therapy"
and conventional chemotherapy.
Terms such as ing" or "treatment" or "to treat" or "alleviating" or “to alleviate”
refer to both 1) therapeutic measures that cure, slow down, lessen symptoms of, and/or halt
progression of a diagnosed pathologic condition or disorder and 2) lactic or
preventative measures that prevent and/or slow the development of a targeted pathologic
condition or disorder. Thus, those in need of treatment e those already with the
disorder; those prone to have the disorder; and those in whom the disorder is to be
prevented. in certain embodiments, a t is sueeessfitliy "treated” for cane-er according
to the s of the present invention if the patient shows one or more of the following:
ion in eaehexia, increase in survival time, elongation in time to tumor progression,
reduction in tumor mass, reduction in tumor burden and/or a prolongation in time to tumor
metastasis, time to tumor recurrence, tumor response, eompiete response, partiai response,
stabie disease, progressive disease, progression tree survival (FPS), overali al (08),
each as measured by standards set by the Nationai Cancer institute and the US. Food and
Drug Administration for the approvai of new drugs. See Johnson et ai, (2003) 3, Che.
Oneoi. 21t?):i404~i41 t.
"Progression free survivai" (PPS), also ed to as or "Time to Tumor
Progression" (YEP) indicates the length of time during and after treatment that the cancer
does not Progression-free survival includes the amount of time patients have
grow.
experéenced a complete response or a partial response, as well as the amount of time
patients have experienced stable disease.
"Disease free survival" (DFS) refers to the length of time during and after ent
that the patient remains free of disease.
"Overall Survival" (OS) refers to a gation in life expectancy as compared to
naive or untreated individuals or patients.
As used in the present disclosure and claims, the singular forms "a," "an," and "the"
e plural forms unless the context clearly dictates otherwise.
It is understood that wherever embodiments are bed herein with the language
"comprising," otherwise analogous embodiments described in terms of "consisting of‘
and/or "consisting essentially of" are also provided.
The term "and/or" as used in a phrase such as "A and/or B” herein is ed to
e both "A and B," "A or B," "A," and "B." Likewise, the term "and/or" as used in a
phrase such as "A, B, and/or C" is intended to encompass each of the ing
ments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and
C; A (alone); B (alone); and C (alone).
11. Biological samples
Biological samples are often fixed with a fixative. Aldehyde fixatives such as
formalin (formaldehyde) and glutaraldehyde are typically used. Tissue samples fixed using
other fixation techniques such as alcohol immersion (Battifora and Kopinski, J. Histochem.
_20e
Cytechem. (ll-$86) 34:109.?) are also suitable. The s used may also be embedded in
n. in one embodiment, the tissue samples are both lbrmalinafixed and paraffin--
embedded (PEPE). in another embodiment, the FFPE block is hematoxylin and ecsin
d prior to selecting ene 01' more portions fer analysis in order to select specific areats)
fer the FFPE core sample. s of preparéng tissue blocks from these particulate
specimens have been used in previous EEC studies cf varicus pregnnstic factors, and/er is
well. known to those of skill in the art (see, for example, Abbcndanzo et al, Am 3 Clin
. @990 l‘vlay;93(5):698»702; Allred et al., Arch Surg. l99t) .Ean;l25(l):lll7—l3).
{@591} Briefly, any intact organ or tissue may be cut into fairly small pieces and incubated
in various es (eg. formalin, alcohol, etc.) for varying periods of time until the tissue
is "fixed". The samples may be virtually any intact tissue ally removed from the body.
The s may be cut into reasonably small piece(s) that fit on the equipment routinely
used in histopathology laboratories. The size of the cut pieces typically ranges from a few
millimeters to a few centimeters.
III. Detection Antibody Conjugates
The present invention further es antibodies against FOLRl, generally of the
monoclonal type, that are linked to at least one agent to form a detection antibody
conjugate. In order to increase the efficacy of antibody molecules as diagnostic it is
conventional to link or ntly bind or complex at least one desired molecule or moiety.
Such a molecule or moiety may be, but is not limited to, at least one reporter molecule. A
reporter molecule is defined as any moiety that may be ed using an assay. Non-
limiting examples of reporter molecules that have been ated to antibodies include
enzymes, radiolabels, haptens, cent labels, phosphorescent molecules,
chemiluminescent molecules, chromophores, luminescent molecules, photoaffinity
molecules, colored particles and/or s, such as biotin.
Any cell binding agent (e.g., an antibody or polypeptide) of sufficient selectivity,
specificity or affinity may be employed as the basis for detection of the FOLRl polypeptide.
Such properties may be evaluated using conventional immunological screening
methodology known to those of skill in the art. Sites for binding to biological active
molecules in the antibody molecule, in addition to the canonical antigen binding sites,
include sites that reside in the variable domain that can bind the antigen. In addition, the
-21“.
variable domain is involved in antibody self—binding (Kang et al., 1988) and contains
epitopes (idiotopes) recognized by anti-antibodies (Kohler et al., 1989).
Certain examples of protein binding (e.g., antibody) conjugates. are those ates
in which the protein binding agent (e.g., antibody) is linked to a able label.
"Detectable labels" are compounds and/or ts that can be detected due to their specific
functional properties, and/or chemical characteristics, the use of which allows the antibody
to which they are attached to be detected, and/or r quantified if desired.
{0095} Many appropriate imaging agents are known in the art, as are methods for their
attachment to antibodies (see, for e.g., US. Pat. Nos. 5,021,236; 4,938,948; and 4,472,509,
each incorporated herein by reference). The imaging moieties used can be paramagnetic
ions; ctive isotopes; fluorochromes; tectable substances; and/or X—ray
imaging, for example.
Exemplary fluorescent labeis contemplated for use as protein binding (e.g.,
antibody) conjugates include Alexa 350, Alexa 430, Alexa 488, AMCA, BODIPY 630/650,
BODIPY 5, BODIPY—FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade
Blue, Cy3, Cy5,6-FAM, Dylight 488, Fluorescein ocyanate, Green fluorescent protein
(GFP), HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific
Blue, Phycoerythrin, REG, Rhodamine Green, Rhodamine Red, tetramethyl rhodamine
(TMR), Renographin, ROX, TAMRA, TET, Tetramethylrhodamine, Texas Red, and
derivatives of these labels (i.e halogenated analogues, modified with isothiocyanate or other
linker for conjugating, etc), for example. An exemplary radiolabel is tritium.
£13097} Protein binding (e.g., antibody) detection conjugates contemplated in the present
invention e those for use in Vitro, where the antibody is linked to a secondary binding
ligand and/or to an enzyme (an enzyme tag) that will generate a colored product upon
contact with a chromogenic substrate. es of suitable enzymes include urease,
alkaline phosphatase, (horseradish) hydrogen dase and/or glucose oxidase. Preferred
ary binding ligands are biotin and/or avidin and avidin nds. The use of
such labels is well known to those of skill in the art and are described, for example, in US.
Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241;
each incorporated herein by reference.
Molecules containing azido groups may also be used to form covalent bonds to
proteins through reactive nitrene intermediates that are generated by low intensity
ultraviolet light (Potter & Haley, 1983). In ular, 2- and 8—azido analogues of purine
nucleotides have been used as site-directed photoprobes to fy nucleotide binding
proteins in crude cell extracts (Owens & Haley, 1987; Atherton et al., 1985). The 2- and 8-
azido nucleotides have also been used to map nucleotide binding domains of purified
ns (Khatoon et al., 1989; King et al., 1989; and Dholakia et al., 1989) and may be used
as antibody binding agents.
Several methods are known in the art for the attachment or conjugation of an
antibody to its conjugate moiety. Some attachment methods involve the use of a metal
chelate x employing, for example, an organic chelating agent such a
diethylenetréaminepentaacetic acid anhydride (DTPA); ethylenetriaminetetraacetic acid; N-
chloro-p-toluenesulfonamide; and/or hloro-3a-6d-diphenylglycouril-3 ed to the
antibody (US. Pat. Nos. 4,472,509 and 4,938,948, each incorporated herein by reference).
Monoclonal antibodies may also be reacted with an enzyme in the presence of a coupling
agent such as glutaraldehyde or periodate. Protein binding (e. g., antibody) conjugates with
fluorescein markers are prepared in the presence of these coupling agents or by reaction
with an isothiocyanate. In US. Pat. No. 4,938,948, g of breast tumors, for example,
is achieved using monoclonal dies, and the detectable imaging es are bound to
the antibody using linkers such as methyl-p-hydroxybenzimidate or N—succinimidyl(4-
hydroxyphenyl)—propionate.
In other embodiments, derivatization of immunoglobulins by selectively introducing
sulfliydryl groups in the Fc region of an immunoglobulin using reaction conditions that do
not alter the antibody ing site are contemplated. Antibody ates ed
according to this methodo‘rogy are disclosed to exhibit improved longevity, specificity and
sensitivity (US. Pat. No. 5,196,066, incorporated herein by reference). Site-specific
attachment of effector or reporter molecules, wherein the reporter or effector molecule is
conjugated to a carbohydrate residue in the Fc region, have also been disclosed in the
literature nnessy et al., 1987).
In other embodiments of the invention, immunoglobulins are radiolabeled with
nuclides such as tritium. In additional embodiments, nanogold particles (such as sizes from
about 0.5 nm-40 nm) and/or Quantum Dots (Hayward, Calif.) are employed.
IV. Enzymes and Substrates (Chromagens)
The use of substrates and tors is contemplated for ion of FOLRl, such as
the ary embodiments provided below, for example.
_23,
adish peroxidase (HRP) is an enzyme that first forms a complex with
hydrogen peroxide and then causes it to decompose, resulting in water and atomic oxygen.
Like many other s, HRP and some ke activities can be inhibited by excess
ate. The complex formed between HRP and excess hydrogen de is catalytically
inactive and in the absence of an electron donor (e.g. genic substance) is reversibly
inhibited. It is the excess hydrogen peroxide and the absence of an electron donor that
brings about ing of endogenous HRP activities.
{00104} When used in assays systems, HRP can also be used to convert a defined substrate
into its activated chromagen, thus causing a color change. The HRP enzyme may be
conjugated to an antibody, protein, peptide, polymer, or other molecule by a number of
methods. Such methods are known in the art. Adding glutaraldehyde to a solution
containing an admixture of HRP and antibody will result in more antibody molecules being
conjugated to each other than to the enzyme. In the two-step procedure, HRP reacts with the
bifunctional reagents first. In the second stage, only activated HRP is d with the
antibody, resulting in much more nt labelling and no polymerization. HRP is also
conjugated to (strept)avidin using the two—step glutaraldehyde procedure. This form is used
in procedures where LAB and LSAB are substrate, for example. Conjugation with biotin
also involves two steps, as biotin must first be derivatized to the yl-N—
hydroxysuccinimide ester or to biotin hydrazide before it can be reacted with the
epsilonamino groups of the HRP enzyme.
] 3,3'—Diaminobenzidine (DAB) is a substrate for enzymes such as HRP that produces
a brown end product that is highly insoluble in alcohol and other organic solvents.
Oxidation of DAB also causes polymerization, resulting in the ability to react with osmium
tetroxide, and thus increasing its staining intensity and electron density. Of the several
metals and methods used to intensify the optical y of polymerized DAB, gold chloride
in combination with silver sulfide appears to be the most successful.
3-Amino—9-ethylcarbazole (ABC) is a substrate for enzymes such as HRP. Upon
oxidation, forms a rose-red end product that is alcohol soluble. Therefore, specimens
processed with ABC must not be immersed in l or alcoholic solutions (e.g., Harris'
hematoxylin). Instead, an aqueous counterstain and mounting medium should be used. ABC
is unfortunately susceptible to further oxidation and, when exposed to excessive light, will
fade in intensity. Storage in the dark is therefore recommended.
4-Chloro-1—naphthol (CN) is a substrate for enzymes such as HRP and precipitates
as a blue end product. Because CN is soluble in alcohol and other organic solvents, the
specimen must not be ated, exposed to alcoholic counterstains, or coverslipped with
mounting media containing organic ts. Unlike DAB, CN tends to diffase from the site
of itation.
p-Phenylenediamine dihydrochloride/pyrocatechol (Hanker-Yates reagent) is a an
electron donor substrate for enzymes such as HRP and gives a lack reaction product
that is insoluble in alcohol and other c solvents. Like polymerized DAB, this reaction
product can be osmicated. Varying results have been achieved with Hanker-Yates reagent in
peroxidase techniques.
[0100} Calf intestine alkaline phosphatase (AP) (molecular weight 100 kD) is an enzyme
that removes (by hydrolysis) and transfers phosphate groups from organic esters by
breaking the P-O bond; an intermediate enzyme-substrate bond is briefly . The chief
metal activators for AP are Mg++, Mn++ and Ca++.
{0101] AP had not been used extensively in immunohistochemistry until publication of the
unlabeled alkaline phosphataseantialkaline phosphatase (APAAP) procedure. The soluble
immune complexes utilized in this procedure have molecular weights of approximately 560
kD. The major advantage of the APAAP ure compared to the PAP technique is the
lack of interference posed by endogenous peroxidase activity. Because of the potential
distraction of endogenous peroxidase activity on PAP staining, the APAAP technique is
recommended for use on blood and bone marrow smears. Endogenous alkaline atase
activity from bone, kidney, liver and some white cells can be ted by the addition of l
min-ft levamisole to the substrate solution, although 5 mM has been found to be more
effective. Intestinal alkaline phosphatases are not adequately inhibited by levamisoie.
In the immunoalkaline phosphatase staining method, the enzyme hydrntyzes
ol phosphate esters (substrate) to phenolic compounds and phosphates. The phenols
couple to ess diazonium salts (chromogen) to produce insoluble, colored azo dyes.
Several different combinations of substrates and chromogens have been used successfully.
Naphthol AS-MX phosphate can be used in its acid form or as the sodium salt. The
chromogens Fast Red TR and Fast Blue BB e a bright red or blue end product,
respectively. Both are soluble in alcoholic and other organic solvents, so aqueous mounting
media must be used. Fast Red TR is red when ng cell smears.
{area} Additional exemplary substrates include naphthol AS—BI phosphate, ol AS-
TR phosphate and 5—bromochloro-3—indoxyl phosphate (BCIP). Other possible
chromogens include Fast Red LB, Fast Garnet GBC, Nitro Blue Tetrazolium (NBT)
iodonitrotetrazolium Violet (INT), and derivatives of the structures, for example.
V. Immunodetection Methods
In still further embodiments, the present invention concerns immunodetection
methods for binding, purifying, removing, quantifying and/or otherwése lly ing
biological components such as a ligand as contemplated by the present invention. The
dies prepared in accordance with the present invention may be ed to detect
wild-type and/or mutant ligand proteins, polypeptides and/or peptides. As described
throughout the present application, the use of wild—type and/or mutant ligand c
antibodies is contemplated. Some immunodetection methods e flow cytometry,
enzyme linked imrnunosorbent assay (ELISA), radioimmunoassay (RIA),
immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent
useful immunodetection
assay, and Western blot to mention a few. The steps of various
methods have been described in the scientific literature, such as, e.g., tle M H and
Ben-Zeev 0, Methods Mol Biol. 1999;109:215-37; Gulbis B and Galand P, Hum Pathol.
199% Dec;24(12):1271—85; and De Jager R et al., Semin Nucl Med. 1993 Apr;23(2):l65-79,
each incorporated herein by reference.
In l, the immunobinding s include obtaining a sample suspected of
comprising ligand n, polypeptide and/or peptide, and contacting the sample with a
first ligand binding peptide (e.g., an anti-ligand antibody) in accordance with the present
invention, as the case may be, under conditions effective to allow the formation of
immunocomplexes.
in terms of antigen detection, the biological sample ed may be any sample
that is suspected of comprising a wild—type or mutant ligand protein-specific antigen, such
as a tissue section or specimen, a homogenized tissue extract, biopsy aspirates, a cell,
separated and/or purified forms of any of the above wild-type or mutant FOLRl-containing
compositions, or even any biological fluid that comes into contact with the tissue, including
blood and/or serum, although tissue samples or ts are preferred.
Contacting the chosen biological sample with the antibody under effective
conditions and for a period of time sufficient to allow the ion of immune complexes
-26,
(prémary immune complexes) is generally a matter of simply adding the antibody
composition to the sample and incubating the mixture for a period of time long enough for
the antibodies to form immune complexes with, i.e., to bind to, any ligand protein antigens
present. After this time, the sample-antibody composition, such as a tissue section, ELISA
plate, dot blot or western blot, will generally be washed to remove any non-specifically
bound antibody species, allowing only those antibodies specifically bound within the
prémary immune complexes to be detected.
In general, the detection of immunocomplex formation is well known in the art and
may be achieved through the application of numerous ches. These methods are
generally based upon the detection of a label or marker, such as any of those radioactive,
fluorescent, biological and enzymatic tags. US. Patents concerning the use of such labels
include US. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 149
and 4,366,241, each orated herein by nce. Of course, one may find additional
advantages h the use of a secondary binding ligand such as a second antibody arid/or
a biotin/avidin ligand binding ement, as is known in the art.
The anti—ligand antibody employed in the detection may itself be linked to a
detectable label, wherein one would then simply detect this label, thereby allowing the
amount of the primary immune complexes in the composition to be determined.
Alternatively, the first antibody that becomes bound within the primary immune complexes
may be detected by means of a second binding agent that has binding affinity for the
dy. In these cases, the second binding agerét may be linked to a detectable label. The
second binding agent is itself often an antibody, which may thus be termed a "secondary"
antibody, or a polymer ion system. The primary immune complexes are contacted
with the labeled, ary binding agent, or antibody/polymer detection system, under
effective conditions and for a period of time ent to allow the formation of secondary
immune xes. The secondary immune complexes are then generally washed to
remove any non-specifically bound labeled secondary antibodies or ligands, and the
remaining label in the secondary immune complexes is then detected.
[0111: Further methods include the detection of primary immune complexes by a two-step
approach. A second g agent, such as an antibody, that has g affinity for the
dy is used to form secondary immune complexes, as described above. After washing,
the secondary immune complexes are contacted with a third binding agent or antibody that
has g affinity for the second antibody, again under effective conditions and for a
.27~
period of time sufficient to ailow the formation of immune complexes {tertiary .
compiexes). The third ligand or dy is iinked to a detectabie iabei, allowing detection
of the tertiary immune complexes thus . This system may provide for signal.
arripiitication if this is desired.
it}: E2} In another embodiment, a biotinylated monoclonal or polyclonal antibody is used to
detect the target antigen(s), and a second step antibody is then used to detect the biotin
attached to the complexed biotin. In that method the sample to be tested is first incubated in
a solution comprising the first step antibody. If the target antigen is present, some of the
antibody binds to the n to form a biotinylated antibody/antigen complex. The
antibody/antigen complex is then ed by incubation in successive solutions of
streptavidin (or avidin), biotinylated DNA, and/or mentary biotinylated DNA, with
each step adding additional biotin sites to the antibody/antigen complex. The amplification
steps are repeated until a suitable level of amplification is achieved, at which point the
sample is incubated in a solution comprising the second step antibody against biotin. This
second step antibody is labeled, as for example wéth an enzyme that can be used to detect
the presence of the antibody/antigen complex by histoenzymology using a chromogen
substrate. With suitable amplification, a protein binding (e.g., antibody) conjugate can be
produced that is macroscopically visible.
Another known method of immunodetection takes advantage of the immuno-PCR
(Polymerase Chain on) methodology. The PCR method uses a
DNA/biotin/streptavidin/antibody complex that is washed out with a low pH or high salt
buffer that releases the antibody. The resulting wash solution is then used to carry out a
PCR reaction with le primers with appropriate controls. In specific ments, the
enormous amplification lity and specificity of PCR can be utilized to detect a single
antigen molecule. Such ion may take place in real-time. For example, the use of
tative real-time PCR is contemplated.
{(3114} In the clinical diagnosis and/or monitoring of patients with various forms of disease,
the detection of a FOLRI mutant, and/or an alteration in the levels of FOLRl, in
comparison to the levels in a corresponding biological sample from a normal subject is
indicative of a t with the disease. However, as is known to those of skill in the art,
such a clinical diagnosis would not necessarily be made on the basis of this method in
isolation. Those of skill in the art are very familiar with differentiating between significant
differences in types and/or amounts of biomarkers, which represent a positive identification,
and/or low level and/or ound changes of biomarkers. Indeed, background expression
levels are often used to form a "cut-off" above which increased detection will be scored as
significant and/or positive.
39115; In one embodiment, immunological detection (by immunohistochemistry) of
FOLRI is scored for both intensity and uniformity (percent of stained cells — membrane
only). Comparative scales for FOLRl expression for intensity correlate as 0 — Negative, 0-
1 — Moderate to Strong, — Moderate, 2-3
- Weak to Moderate, 2
- Very Weak, 1 — Weak, 1-2
3 — Strong. tatively, Score 0 represents that no membrane staining is observed in
tumor cells. A Score 1 represents a faint/barely perceptible membrane staining in tumor
cells. For Score 2, a moderate membrane staining is observed in tumor cells. Lastly, Score
3 or 3+ represents a moderate to strong membrane staining in the tumor cells. Those
samples with 0 or 1 score for FOLRI expression may be characterized as not
overexpressing FOLRl, whereas those samples with 2 or E scores may be terized as
overexpressing FOLRI. Samples pressing FOLRl may also be rated by
immunohistochemical scores corresponding to the number of copies of FOLRI les
expressed per cell, and have been determined biochemically: 0=0-10,000 copies/cell, l=at
least about 200,000 copies/cell, 2=at least about 500,000 copies/cell, and 3=at least about
2,000,000 copies/cell. Comparative scales for FOLRl percent cell membrane staining
uniformity correlate as follows: 0 — Negative, Focal - 25-
- <25%, heterogeneous (hetero)
75%, and homogeneous (homo) - >75%.
VI. Nucleic Acid Hybridization
In situ hybridization is lly carréed out on cells or tissue sections fixed to
slides. In situ hybridization may be performed by l conventional methodologies (See
for e.g. Leitch et al. In situ Hybridization: a cal guide, Oxford BIOS Scientific
Publishers, copy handbooks v. 27 (1994)). In one in situ procedure, fluorescent dyes
(such as fluorescein isothiocyanate (FITC) that fluoresces green when d by an Argon
ion laser) are used to label a nucleic acid ce probe that is complementary to a target
nucleotide sequence in the cell. Each cell comprising the target nucleotide sequence will
bind the labeled probe, producing a fluorescent signal upon exposure of the cells to a tight
source of a wavelength riate for excitation of the specific fluorochrome used.
Various degrees of hybridization stringency can be employed. As the hybridization
conditions become more stringent, a greater degree of complementarity is required between
-29..
the probe and target to form and maintain a stable duplex. Stringency is increased by raising
temperature, lowering salt concentration, or raising formamide concentration. Adding
n sulfate or raising its tration may also increase the effective concentration of
labeled probe to increase the rate of ization and ultimate signal intensity. After
hybridization, slides are washed in a solution generally comprising reagents similar to those
found in the hybridization solution with washing time varying from minutes to hours
depending on required stringency. Longer or more stringent washes typically lower
nonspecific background but run the risk of decreasing overall sensitivity.
{aria} Probes used in nucleic hybrédization analysis may be either RNA or DNA
oligonucleotides or polynucleotides and may contain not only naturally-occurring
nucleotides but their analogs, like genin dCTP, biotin dcTP 7—azaguanosine,
azidothymidine, inosine, or uridine, for example. Other useful probes include peptide probes
and analogues thereof, branched gene DNA, peptidometics, peptide nucleic acid (PNA)
and/or antibodies, for example.
{911§§ Probes should have sufficient complementarity to the target nucleic acid sequence of
interest so that stable and specific binding occurs between the target nucleic acid sequence
and the probe. The degree of homology required for stable hybridization varies with the
stringency of the hybridization medium and/or wash medium. Preferably, completely
homologous probes are employed in the present invention, but s of skill in the art will
readily iate that probes exhibiting lesser but sufficient homology can be used in the
present invention (see for e.g. Sambrook, J., Fritsch, E. F., Maniatis, T., lar Cloning
A Laboratory Manual, Cold Spring Harbor Press, (1989)).
{@129} Probes may also be generated and chosen by several means including, but not
d to, mapping by in situ ization, somatic cell hybrid panels, or spot blots of
sorted chromosomes; chromosomal linkage is; or cloned and isolated from sorted
chromosome libraries from human cell lines or somatic cell hybrids with human
chromosomes, radiation c cell hybrids, issection of a chromosome region, or
from yeast artificial somes (YACs) identified by PCR primers c for a unique
chromosome locus or other suitable means like an adjacent YAC clone. Probes may be
genomic DNA, cDNA, or RNA cloned in a d, phage, cosmid, YAC, Bacterial
Artificial Chromosomes (BACS), viral vector, or any other suitable vector. Probes may be
cloned or synthesized chemically by conventional methods. When cloned, the isolated probe
nucleic acid nts are typically inserted into a vector, such as lambda phage, pBR322,
M13, or vectors containing the SP6 or T7 promoter and cloned as a library in a bacterial
host. [See for e.g. Sambrook, J., Fritsch, E. F., Maniatis, T., Molecular Cloning A
tory Manual, Cold Spring Harbor Press, (1989)].
{$122} Probes are preferably labeled, such as with a fluorophor, for example. Examples of
fluorophores e, but are not limited to, rare earth es (europium chelates), Texas
Red, rhodamine, fluorescein, dansyl, Lissamine, iferone, phycocrytherin,
phycocyanin, or commercially available fluorophors such SPECTRUM ORANGETM and
SPECTRUM GREENTM and/or derivatives of any one or more of the above. Multiple
probes used in the assay may be labeled with more than one distinguishable fluorescent or
pigment color. These color differences provide a means to identify the hybridization
positions of specific probes. Moreover, probes that are not separated lly can be
identified by a different color light or pigment resulting from mixing two other colors (e.g.,
light een=yellow) pigment (e.g., blue+yellow=green) or by using a filter set that
passes only one color at a time.
Probes can be labeled directly or indirectly with the fluorophor, utilizing
conventional methodology known to one with skill in the art.
VII. ion Kits and Compositions
Also provided by the invention are kits for use in the practice of the present
invention as disclosed herein. Such kits may se containers, each with one or more of
the various reagents (typically in concentrated form) ed in the methods, including, for
example, one or more binding agents (antibodies), already attached to a marker or
optionally with reagents for coupling a binding agent to an antibody or nucleic acid
molecule (as well as the marker itself); buffers, the appropriate nucleotide triphosphates
(e.g. dATP, dCTP, dGTP, dTTP, dUTP, ATP, CTP, GTP and UTP), reverse transcriptase,
DNA polymerase, RNA polymerase, and one or more sequence-specific or rate
prémers for use in detection of nucleic acid molecules by amplification; and/or reagents and
instrumentation for the isolation (optionally by microdissection) to t the practice of
the ion. A label or indicator describing, or a set of instructions for use of, kit
components in a ligand detection method of the present invention, will also be typically
included, Where the instructions may be associated with a package insert and/or the
packaging of the kit or the components thereof.
-31...
In still further embodiments, the present invention concerns immunodetection kits
for use with the immunodetection methods described above. As the antibodies are generally
used to detect wild—type and/or mutant proteins, polypeptides and/or peptides, the antibodies
will preferably be included in the kit. The immunodetection kits will thus comprise, in
suitable container means, a first antibody that binds to a wild-type and/or mutant protein,
polypeptide and/or peptide, and/or optionally, an immunodetection reagent and/or further
optionally, a wild-type and/or mutant protein, polypeptide and/or peptide.
The immunodetection reagents of the kit may take any one of a variety of forms,
including those detectable labels that are associated with and/or linked to the given
dy. Detectable labels that are associated with and/or attached to a secondary binding
ligand are also contemplated. Exemplary secondary ligands are those secondary dies
or polymers that have g y for the first antibody.
Further suitable immunodetection reagents for use in the present kits e the
two—component reagent that comprises a secondary antibody that has binding affinity for the
first antibody, along with a third antibody or polymer that has binding affinity for the
second antibody, the third antibody being linked to a detectable label. As noted above, a
number of exemplary labels are known in the art and/0r all such labels may be suitably
ed in connection wéth the present invention.
The kits may further comprise a suitably aliquoted composition of the wild-type
and/or mutant protein, polypeptide and/or polypeptide, r labeled and/or unlabeled, as
a n may be used to prepare standard curve for a detection assay. The kits may
dy- or polymer-label ates either in fully conjugated form, in the form of
intermediates, and/or as separate moieties to be conjugated by the user of the kit. The
components of the kits may be packaged either in aqueous media and/or in lized
form.
{0123] The container means of the kits will generally include at least one vial, test tube,
flask, bottle, syringe and/or other container means, into which the antibody may be placed,
and/0r preferably, ly aliquoted. The kits of the present invention will also typically
include a means for containing the antibody, antigen, and/or any other reagent containers in
close confinement for commercial sale. Such containers may e injection and/or blow-
molded plastic containers into which the desired Vials are retained.
gnzw The kits may further comprise one or more therapeutic agents for the treatment of
cancer, such as a FOLRl immunoconjugate and/or a chemotherapeutic agent.
-32..
terse; The kit may further comprise an a FOLRl detection reagent used to measure FOLRl
expression in a t comprésing a FOLRl detection reagent, and instructions for use. In
one embodiment, the FOLRl detection reagent comprises a FOLR] binding peptide, protein
or a lar probe (i.e. nucleic acid). In another embodiment, the FOLRl detection
reagent is an anti-FOLRl antibody. In r embodiment, the kit further comprises a
secondary antibody which binds the OLRI antibody. In one embodiment the FOLRl-
specific antibody is included at a concentration of 0.5 to 7.5 ug/ml, ably 0.9 to 3.8 +/—
0.5 ug/ml. In another embodiment, the dy is included at a concentration of 1.0 +/- 0.5
ug/ml, 1.5 +/— 0.5 ug/ml, 1.9 +/- 0.5 ug/ml, 2.5 +/- 0.5 ug/ml, 3.0 +/- 0.5 ug/ml, 3.5 +/— 0.5
ug/ml, 3.8 +/- 0.5 ug/ml, or up to 4.2 ug/nil. In another embodiment, the antibody is
included in trated solution with instructions for ons to achieve a final
concentration of 0.9 to 3.8 +/- 0.5 ug/ml. In another embodiment, the kit further comprises
a detection reagent selected from the group consisting of: an enzyme, a fluorophore, a
radioactive label, and a luminophore. In another embodiment, the detection reagent is
selected from the group consisting of: biotin, digoxigenin, fluorescein, m, and
ine.
{$131} The kit can also include instructions for detection and scoring of FOLRl expression.
The kit can also include control or reference samples. miting examples of control or
reference samples include cell pellets or tissue culture cell lines derived from normal
(normal control) or tumor (positive control) samples. Exemplary cell lines include KB,
NCI-H2llO, Igrov-l, Ishikawa, Jeg-3, Skov-3, Hela, T47D, Caco2, SW620, OAW28,
HCC827, Ovcar—8, and Ovcar-3, OV—90, other tumor cell lines known to express FOLRI,
and cell lines stably or transiently transfected with an expression vector that expresses
FOLRl. Additional es for positive control tissues can also be found in Examples 9-
11. The kit can also comprise a staining guide which Visually depicts positive and normal
reference samples for staining intensity and uniformity. Such staining guides can have
reference samples from normal lung, pancreas, and/or salivary gland, and stained tumors
with standardized scores (e.g., ovarian, lung, renal, and endometrial s, as well as
those described in the Examples and in Figures 23—25)
VIII, FOLifilubinding agents
Any dies that bind FOLRI can be used in the detection methods of the present
invention. es oftherapeuticaily effective anti—FOLRI antibodies can be tbund in US
Appl. Pub. No. US 2012/0009181 which is herein incorporated by reference. The fulllength
amino acid (aa) and nucleotide (nt) sequences for FOLR1 are known in the art
and also provided herein as represented by SEQ ID NOs: 1 and 2, respectively. A
specifically useful antibody for detection of FOLR1 is the mouse monoclonal antihuFOLR1
clone BN3.2 (Leica # NCL-L-FRalpha). An example of a therapeutically
effective OLR1 antibody is huMov19 (M9346A). The polypeptides of SEQ ID
NOs: 3-5 comprise the variable domain of the heavy chain of huMov19 (M9346A), and
the variable domain light chain version 1.00, the variable domain light chain version
1.60 of huMov19, respectively. The huMov19 (M9346A) antibody comprises: (a) a
heavy chain CDR1 comprising GYFMN (SEQ ID NO:6); a heavy chain CDR2
comprising RIHPYDGDTFYNQKFQG (SEQ ID NO:7); and a heavy chain CDR3
comprising YDGSRAMDY (SEQ ID NO:8); and (b) a light chain CDR1 comprising
KASQSVSFAGTSLMH (SEQ ID NO:9); a light chain CDR2 comprising RASNLEA
(SEQ ID NO:10); and a light chain CDR3 comprising QQSREYPYT (SEQ ID NO:11).
In certain embodiments, the 9 (M9346A) antibody is encoded by the plasmids
ted with the American Type Culture Collection (ATCC), located at 10801
University Boulevard, Manassas, VA 20110 on April 7, 2010 under the terms of the
Budapest Treaty and having ATCC t nos. PTA-10772 and PTA-10773 or 10774.
Examples of FOLR1 immunoconjugates useful in the therapeutic methods of the
invention are ed below.
IX. FOLR1 Immunoconjugates
The present invention also includes methods for sing the efficacy of
conjugates (also ed to herein as immunoconjugates), comprising the anti-FOLR1
dies, antibody fragments, functional equivalents, improved antibodies and their
aspects as disclosed , linked or conjugated to a cytotoxin (drug) or g.
Exemplary FOLR1 immunoconjugates can be found in US Appl. Pub. No. US
009181, which is herein incorporated by reference. A particularly effective
therapeutic immunoconjugate of the invention comprises the huMov19 antibody
described above.
Suitable drugs or prodrugs are known in the art. In certain embodiments, drugs
or prodrugs are xic agents. The cytotoxic agent used in the cytotoxic ate of
the present invention can be any compound that results in the death of a cell, or induces
cell death, or in some manner decreases cell viability, and includes, for example,
maytansinoids and maytansinoid analogs, benzodiazepines, taxoids, CC-1065 and CC-
1065 analogs, duocarmycins and duocarmycin analogs, enediynes, such as
calicheamicins, atin and dolastatin analogs including auristatins, tomaymycin
derivatives, leptomycin derivatives, rexate, cisplatin, carboplatin, daunorubicin,
doxorubicin, vincristine, vinblastine,
[TEXT CONTINUES ON PAGE 35]
- 34a -
melphaian, mitoh’tyciri C, mbucii and morphoiirio doxombicin, In certain
embodiments, the cytotoxic agents are maytansinoids and sirioids analogs,
{0135} The drug or prodrug cart, for exampie, be limited to the anti—FOLK antibody, such
as hul‘vtoviéi, or fragment thereof through a disulfide bond. The iinirer molecule or
crosslinking agent comprises a reactive chemical group that can react with the airtix-FOLRl
antibody or tragn‘tent f, in certain embodiments, ve ai groups for
reaction with the cell—binding agent are ,NLSticciitimidyi esters and. Neuifosuccinimidyi
esters. onaliy the linker molecule comprises a reactive chemical group, in certain
embodiments a opyridyl group that can react with the drug to form a disuitide bond. in
certain embodiments, ticker molecules inciude, for example, ccinimidyi 3«{2~
pyridyidithio} propionate (SPDP) (see, cg, Cartsson et ai‘, Biochem. J, {173: 723337
)g A’T—SUCCiHitnidyi 4-«(2:pyridyidithiokutaiioate (SPDB) (see, eg US: Patent No.
4,563,304): i\7l~3ttccininiidyi 4*(2*pyridyidithioiflm-suifobutanoate (sulfo-SPDB) (see US
Publication No. 20090274713) , inimidyl 4—(2—pyridyldithio) pentanoate (SPP) (see,
e.g., CAS Registry number 341498-08—6), 2-iminothiolane, or succinic anhydride.
Antibody-maytansinoid conjugates with non-cleavable links can also be prepared.
Such crosslinkers are described in the art (see ThermoScientific Pierce Crosslinking
Technical Handbook and US Patent Application Publication No. 2005/0169933) and
include but are not d to, N—succinimidyl 4-(maleimidomethyl)
cyclohexanecarboxylate (SMCC), inimidyl—4-(N-maleimidomethyl)-cyclohexane—l-
carboxy—(6-amidocaproate), which is a “long chain” analog of SMCC (LC—SMCC), K-
maleimidoundecanoic acid N—succinimidyl ester (KMUA), B-maleimidopropanoic acid N-
succinimidyl ester (BMPS), y—maleimidobutyric acid N-succinimidyl ester (GMBS), 8-
maleimidocaproic acid N—hydroxysuccinimide ester (EMCS), m-maleimidobenzoyl—N-
hydroxysuccinimide ester (MBS), N-(oc-maleimidoacetoxy)-succinimide ester (AMAS),
succinimidyl-6—(B-maleimidopropionamido)hexanoate (SMPH), N-succinimidyl 4—(p-
idophenyl)~butyrate (SMPB), and N—(p-maleimidophenyl)isocyanate (PMPI), N-
succinimidyl(iodoacetyl)—aminobenzoate (SIAB), N-succinimidyl iodoacetate (SEA), N—
succinimidyl bromoacetate (SBA), and N-succinimidyl 3-(bromoacetamido)propionate
(SBAP). In certain embodiments, the antibody is modified with crosslinking reagents such
as succinimidyl 4—(N-maleimidomethyl)—cyclohexane—l-carboxylate (SMCC), sulfo—SMCC,
maleimidobenzoyl-N—hydroxysuccinimide ester (MBS), sulfo—MBS or succinimidyl-
iodoacetate, as described in the literature, to introduce l-lO reactive groups (Yoshitake et a1,
Eur. J. Biochem, 101:395-399 (1979); Hashida et al, J. Applied m., 56—63 (1984);
and Liu et at, Biochem, 182690-697 ).
The present invention includes s wherein about 2 to about 8 drug molecules
("drug load"), for example, maytansinoid, are linked to an anti-FOLRl antibody or fragment
thereof, the anti-tumor effect of the conjugate is much more efficacious as compared to a
drug load of a lesser or higher number of drugs linked to the same cell binding agent.
"Drug load", as used herein, refers to the number of drug les (e.g., a maytansinoid)
that can be attached to a cell binding agent (e.g., an anti-FOLRl antibody or fragment
thereof). In one aspect the number of drug molecules that can be attached to a cell binding
agent can average from about 2 to about 8 (e.g., 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8,
2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9,
.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0,
7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1). In n embodiments, the drug is N21
deacetyl—NT-(3—mercapto-l-oxopropyl)—maytansine (DMl) or N27—deacetyl—N2’-(4-mercapto-
4-methyl-l-oxopentyl) maytansine (DM4). Thus, in a certain embodiment, the antibody
huMovl9 is conjugated to DMI or DM4. In another embodiment, the antibody FR—l-21 is
conjugated to DMl or DM4. In r embodiment, the antibody FR-l-48 is conjugated to
DMl or DM4. In another embodiment, the antibody FR—1-49 is conjugated to DMl or
DM4. In r embodiment, the dy FR—l—57 is ated to DMl or DM4. In
another embodiment, the antibody FR—l-65 is conjugated to DMl or DM4.
X. ation of FOLRl sion and therapeutic efficacy ’
In certain embodiments, the invention provides a method for identifying subjects
with an increased likelihood for responding to FOLRl-targeting anti-cancer therapies. The
invention is based, in part, on the discovery that elevated FOLRl expression levels
correlates with efficacy of FOLR-l -targeting anti-cancer therapeutics.
Evaluation of patient samples and correlation to in vivo efficacy using xenograft
models demonstrates the power of the expression analysis for selecting subjects more likely
to respond to treatment. IHC provides a score for FOLRl expression on tumor cells: 0 (no
expression) to 3+ (very high levels of expression). In vivo data using xenograft models
demonstrates that samples scoring 1, 2, 3, or 3+ for FOLRl expression, preferably a score
of 2, 3, or 3+, have an increased likelihood to respond to FOLR—l-targeted anti-cancer
therapies at clinically-relevant doses of FOLRl conjugates (e.g., 5 mg/kg xenograft
-36~
dose of a FOLRI immunoconjugate can approximate a 185 mg/m2 in patients). Thus,
identification of individuals having an elevated FOLRl score would help identify those
duals who might respond to a clinically relevant . As described in more detail
below, sensitivity to FOLRI eutics correlated with FOLRl scoring of 2 or higher,
especially with level 3 scoring. Moreover, expression of more uniform levels of FOLRl
provides better correlation with therapeutic benefit. Thus, a homogeneous staining
uniformity is preferred but combinations of increased staining intensity with heterogeneous
staining mity are also indicative of increased FOLRl expression. For example, scores
of greater than 2 hetero is a patient selection criterion for treatment with a FOLRl
therapeutic agent.
{(31%} FOLRl expression analysis also identifies patients in whom decreased levels of a
FOLRl-targeting anti-cancer therapy ("low dose therapy") can be effective to cause anti-
tumor responses. As is appreciated in the art, compounds are generally administered at the
st dosage that achieves the desired eutic response. This is specifically
important for therapeutics that cause clinical, and often undesired, side effects. The ability
to recognize those subjects with elevated FOLRl expression levels allows for minimization
of the dosage of the FOLR-l—targeting therapeutic, thus decreasing le side effects,
while ining therapeutic efficacy.
{M41} As shown herein, FOLRl expression scores of 2 hetero or greater correlate with
increased siveness to anti—FOLRI immunoconjugates. In certain embodiments, the
increased responsiveness is cachexia, increase in survival time, elongation in time to tumor
progression, reduction in tumor mass, reduction in tumor burden and/or a prolongation in
time to tumor metastasis, time to tumor recurrerice, tumor response, complete se,
l response, stable e, progressive disease, progression free al (PFS), or
overall survival (OS). In certain embodiments, FOLRl expression scores of 2 hetero or
greater correlate with increasing PFS, DFS, or OS.
Kits for use in the detection methods and correlation to reference/control s
can comprise control (positive and/or negative) or reference samples. The positive control
or positive reference samples can be derived from tissue culture cell lines, normal tissue
tumor tissue. Positive and negative reference samples can be d from cell lines
including SW620, T47D, IGROV-l, HeLa, KB, EEG-3, other tumor cell lines, and cell lines
stably or transiently transfected with an expression vector that encodes FOLRl. Normal or
turner tissue samples and tissue culture eeii Eines can also be used as a negative central
reference s. Fer additienai sampies, see Examples 9—} I and Figures 22.3»25.
XI. Pharmaceutical compositions and therapeutic methods
{@143} FOLRl-binding agents (including antibodies, immunoconjugates, and ptides)
are useful in a variety of applications including, but not limited to, therapeutic treatment
methods, such as the treatment of cancer. In certain embodiments, the agents are useful for
inhibiting tumor growth, inducing differentiation, reducing tumor volume, and/or reducing
the tumorigenicity of a tumor. The methods of use may be in vilro, ex vivo, or in viva
methods. In certain embodiments, the FOLRl-binding agent or antibody or
immunoconjugate, or polypeptide is an nist of the human FOLRI to which it binds.
{$144} In n embodiments, the disease treated with the FOLRl—binding agent or
antagonist (e.g., a huMovl9 antibody or immunoconjugate) is a cancer. In certain
embodiments, the cancer is characterized by tumors expressing folate receptor 1 to which
the FOLRl-binding agent (e.g., antibody) binds.
The present invention provides for s of treating cancer comprising
stering a therapeuticaliy effective amount of a inding agent to a subject
(e.g., a subject in need of treatment). In certain embodiments, the cancer is a cancer
selected from the group consisting of colorectal , pancreatic cancer, lung cancer,
ovarian cancer, liver cancer, breast cancer, brain cancer, kidney cancer, prostate cancer,
gastrointestinal , melanoma, cervical cancer, bladder , glioblastoma, and head
and neck . In n embodiments, the cancer is ovarian cancer. In certain
embodiments, the cancer is lung cancer. In certain embodiments, the subject is a human.
The present invention further provides methods for inhibiting tumor growth using
the antibodies or other agents described herein. In certain ments, the method of
inhibiting the tumor growth comprises contacting the cell with a FOLRl-binding agent
(e.g., antibody) in Vitro. For example, an immortalized cell line or a cancer cell line that
expresses FOLRI is cultured in medium to which is added the antibody or other agent to
inhibit tumor growth. In some embodiments, tumor cells are isolated from a patient sample
such as, for example, a tissue biopsy, pleural effusion, or blood sample and ed in
medium to which is added an FOLRl -binding agent to inhibit tumor growth.
In some embodiments, the method of ting tumor growth comprises contacting
the tumor or tumor cells with the FOLRl-binding agent (e.g., antibody) in Vivo. In certain
embodiments, contacting a tumor or tumor cell with a FOLRl-binding agent is undertaken
in an animal model. For e, FOLRl-binding agents can be administered to xenografts
expressing one or more FOLRls that have been grown in immunocompromised mice (e.g.
NOD/SCID mice) to inhibit tumor growth. In some ments, the FOLRE—binding
agent is administered at the same time or shortly after introduction of tumorigenic cells into
the animal to prevent tumor growth. In some embodiments, the FOLRl-binding agent is
administered as a eutic after the tumorigenic cells have grown to a specified size.
{$148} In certain embodiments, the method of inhibiting tumor growth compréses
administering to a subject an therapeutically effective amount of a FOLRl-binding agent.
In certain embodiments, the subject is a human. In certain embodiments, the subject has a
tumor or has had a tumor removed.
In certain embodiments, the tumor is a tumor selected from the group consisting of
brain tumor, colorectal tumor, pancreatic tumor, lung tumor, ovarian tumor, liver tumor,
breast tumor, kidney tumor, prostate tumor, gastrointestinal tumor, melanoma, cervical
tumor, bladder tumor, glioblastoma, and head and neck tumor. In certain embodiments, the
tumor is an ovarian tumor.
{915%} In certain embodiments, the invention es methods of ting tumor growth
using low doses of a FOLRl-binding agent. The term "low dose" as used herein refers to
the eutically effective dose of a FOLRl—binding agent which is less than the usual or
the conventional dose required to produce the therapeutic effect.
Thus, in certain embodiments the inventions provides methods of treating cancer
using huMovl9 antibody and immunoconjugates. In n embodiments, the huMovl9
conjugate is huMovl9-SPDB-DM4; huMovl9-sulfo-SPP-DM1; 9—SPF-
DMI; or huMovl9-PEG4-Mal-DM4. In a certain embodiment, the huMovl9
immunconjuage is huMovl9-SPDB-DM4, which is also referred to as IMGN853.
{$152} In certain embodiments, formulations are prepared for storage and use by combining
a purified antibody or agent of the present invention with a pharrnaceutically acceptable
vehicle (e.g. carrier, excipient) (Remington, The e and Practice of cy 20th
Edition Mack hing, 2000). Suitable pharmaceutically acceptable vehicles include, but:
are not limited to, nontoxic buffers such as phosphate, citrate, and other organic acids; salts
such as sodium chloride; antioxidants including ascorbic acid and nine; preservatives
(e.g. cyldimethylbenzyl ammonium chloride; hexamethonium chioride;
benzalkonium chloride; benzethonium chloréde; phenol, butyl or benzyl alcohol; alkyl
parahens, such as methyl or propyl paraben; cateehol; resorcinol; cyclohexanol; 3~pentanoh
and ItiaCI‘t‘fiSQl/i; low molecular weight ptides (cg. less than about it} amino acid
residues); proteins such as serum albumin, gelatin, or oglohulins; hydrophilie
polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine,
histidine, arginine, or lysine; carbohydrates such as monosaccharides, disaccharides,
glucose, niarniose, or destrins; chelating agents such as Eli)’l‘A; sugars such as sucrose,
mannitol, ose or sorbitol; saltmt‘onning counter—ions such as sodium; metal complexes
(cg. Lin—protein complexes); and nic surfactants such as 'l‘W'lEElEN or polyethylene
glycol (PEG).
{eras} The pharmaceutical itions of the present invention, can be stered in
Administration can be topical
any number ot‘ ways for either local or systen'iic treatment.
{such as to mucous membranes including l and rectal delivery) such as transdermal
patches, ointntents, lotions, creams, gels, drops, suppositories, sprays, liquids and powders;
pulmonary (cg, by inhalation or insufflation of powders or aerosols, including by
nehulizer; intratracheal, intranasal, epidermal and transdennal); oral; or parenteral including
intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or
infusion; or intracranial leg, hecai or intraventricnlar) administration.
{@154} An antibody or iimnunoconiugate of the invention can be combined in a
pharmaceutical combination formulation, or dosing regimen as combination therapy, with a
second compound having ancer properties. The second compound of the
pharmaceutical combination tonnulation or dosing regimen preferably has complementary
activities to the ADC of the combination such that they do not adversely affect each other.
Pharmaceutical itions comprising the FOLRl-hinding a;\4 ant and the second anti»
cancer agent are also provided.
U} U! For the ent of the disease, the appropriate dosage of an antihody or agent of
the present invention depends on the type of disease to he treated, the severity and course of
the e, the responsiveness of the disease, whether the antibody or agent is administered
for therapeutic or preventative purposes, previous therapy, patient’s clinical y, and so
on all at the discretion of the treating physician. ”l‘he dy or agent can he administered
one time or over a series oftreatinents lasting from several days to several months, or until a
cure is effected or a tion of the disease state is achieved {eg reduction in turner
sire). Optimal dosing schedules can he calculated from measurements of drug
accumulation in the hotly of the patient and will vary depending on the relative potency of
-49“
an individual antibody or agent. The administering physician can easily ine m
dosages, dosing methodologies and repetition rates. In certain embodiments, dosage is from
0.0] ug to 100 mg per kg of body weight, and can be given once or more daily, weekly,
monthly or yearly. In certain embodiments, the antibody or other FOLRl-binding agent is
given once every two weeks or once every three weeks. In certain embodiments, the dosage
of the antibody or other binding agent is from about 0.1 mg to about 20 mg per kg
of body weight. The treating physician can te repetition rates for dosing based on
measured residence times and concentrations of the drug in bodily fluids or s.
{eissi The combination therapy can provide "synergy" and prove "synergistic", i.e. the
effect ed when the active ingredients used together is greater than the sum of the
effects that results from using the compounds separately. A synergistic effect can be
attained when the active ingredients are: (l) co-formulated and administered or delivered
simultaneously in a combined, unit dosage formulation; (2) delivered by alternation or in
parallel as separate formulations; or (3) by some other regimen. When delivered in
alternation therapy, a synergistic effect can be attained when the compounds are
administered or delivered sequentially, e.g. by different injections in separate syringes. In
general, during alternation therapy, an effective dosage of each active ingredient is
administered sequentially, i.e. serially, whereas in combination therapy, effective dosages of
two or more active ingredients are administered er.
{3157} Embodiments of the present disclosure can be r defined by nce to the
ing non-limiting examples, which describe in detail preparation of certain antibodies
of the present disclosure and methods for using antibodies of the present disclosure. It will
be apparent to those skilled in the art that many modifications, both to materials and
methods, can be practiced t departing from the scope of the present sure.
EXAMPLES
It is understood that the examples and embodiments described herein are for
illustrative puposes only and that various modifications or changes in light thereof will be
ted to persons skilled in the art and are to be included within the spirit and purview of
this application.
The Folate Receptor-l (FOLRl) has been reported to be highly expressed in ovarian
tumors and expressed at high to moderate levels in brain, , bladder, endometrioid,
-41,
lung, pancreatic, and renal carcinomas. However, the expression of FOLK} is limited in
normal tissues and includes kidney, lung, d plexus, pancreas, breast, thyroid? ovary,
te, and lung.
{316%} Methods have been reported that quantify FOLRl using fresh frozen tissue
nates. Whole ”tissue homogenates cannot distinguish cytoplasmic from membraneassoeiated
expression and y frozen samples are not amenable in the clinical setting.
However, formalin fixed paraffin embedded {FFPE} samples can be archived for patients in
the clinic.
Exempie i
{($161} lininunolzistoehemieal staining of FQLRl in cell, samples - manual s
Fornialin fixed paraffin embedded eeli s and tissues were used as test samples with the
following staining reagents and eoni‘litions.
lHC Antibodies FFPE assay conditions
l‘ """ W} MMWW...“
l..16?,_ Amihie—M...“_ l"SEB§H_NNMM““ COHdlthI’lfi' ' mmmm“
e mouse onal anti-hiiFOLRl Antigen val Borg (Biocaré) PH
clone BN32 (Leiea # Ni; E.-L-
lRalpha)
Avidin/Biotin;
: Blocking Steps
iimmnnoflen: Piokai‘yotie inant mwwipergggie
protein corresponding :0 189 amino Test or Control 2.0 ug/mL
aeia‘ls ofthe external domain ofthe folate Article
We“ a135131014111ij ipfluem mammo2%‘
lCOfllI‘G} A i i‘horseserurnfi
{giggles} (miner: Clone we eeozsii Secondary Antib9dy l 10 ng/rnL
‘fieeondaryAnilmd‘i’ ‘Detection System* i AVidin-Biotin- i
ieBiotinVlated horse anti-mouse (Veetor, peroxidase- l
ione ijis1&le> Complex; ABC
(Vector Labs)
i i DAB(DakoL
> 5 min E
39162} E‘onnaiin—fixed paraffin-embedded (FFPE) patient. ovarian tumor biopsies and
ovarian xenogral’i tumors were stained with the murine anti-FQLRi antibody elone BNEQ,
(Leica Cat 4N(.ll-lRalplia) and a conmi nulls“(3‘1 fioni Conner. Following antigen
retrieval in pH 9.5 buffer, slides were blocked with 2% horse serum plus avidin. Slides were
washed in PBS, and incubated at reein temperature fer {if} minutes with the attti~FOlRl er
eentrel mitigGl antibetiy, followed by 30 minutes with laintinylated anti—meme lgsfi and 4G
minntee with avidinbiotinperoxidase eemplex to detect bound secendary antibeiyi
incubation for 5 minutes with DAB (33 xfifibtjl’lv’lflllle tetralmtreehlerid.) resultedin
the color signal. Slides were eeenterstained with hematexyiin
Ri staining intensity and distrihution patterns were seated relative to central
lgG staining {_nenepeeifie). Intensity was sceie01 en a scale of O 1103 (O-==no staining, 1 :
weak, 2 = moderate and 3 strong) and distribution was scored as focal (<25% ei’ cells
stained), heterogeneous (25-75% of cells stained) and homogeneous (>75% of cells
stained).
FFPE samples were d from tumor micro arrays, as well as human tissue
blocks from seven different , as outlined below.
EFF}? Test Samples
_\\“\“\\“\“““
i“lltrnan Tenet Miere \nays DthllpilOfi Commerc1al Source 5
il“A“
96__cores from ”3 types of cancer3—3_________________________________________________ eMued tumet BiomaxCat# MC961
eOt-ariantame} _6_4_ cores _M a1nCat# T8235725t
i$38le _
9Ie__s_ B10maxCat#L%
eCeleimtal ma :85 ate cores B10maXCat#BC000110
“——“T‘“”
ElemMeme sNILraher cial So ce
LeBreast 'l'nmeru
etlel ereetal Carei
“““““““ CHTN
{$1653 The FOLRl test article, marine anti~FOLRi atone BN32, was tested to determine
binding speeiticit‘v tn the huFOLRl antigi.1}. Using tne reperted IHC staining methods
FFPE sections of 30049 and 300—19 transfeeted with huFCfiLRi (3004(Ii/FO'LRL) cell
pellets were stained and evaiuated fer FOUU. The FOLRl test article specifically stained
300~l9/FOLR1+ cells and retumed tie staining in 38049 cells (3 home and negative,
-43,
respectively). These s demonstrate that clone BN3.2 specifically targets the huFOLRl
n. (Figure l).
The BN3.2 antibody was also used to detect FOLRl expression on tissue samples.
The immunoreactivity of each test and control article with tissues and cell pellets was
determined by the consulting pathologist, Dr. David Dorfman. The cell pellet controls were
first evaluated followed by tissue samples. For each tissue evaluated, a ption of the
staining intensity and staining uniformity was reported. The staining intensity score and
uniformity scales are described below. The final reported score for each tissue sample
ted is the score of the test article minus the score of the respective l article.
The ABC level for each sample was estimated by comparing the staining score to the
calibrated cell pellet ls.
InLeHSIty(amountofstaln) l Tlnil‘urmiiy (nmnberafstained cells}
: \
\“i 0 ve
\ :
lwwweak ,__M_, olNegatwe
2 Moderate FOC31¢E<2V
Strong Heterogeneous(hetero)E2575/
"""" """""""""veryStronrlHomogeneous(homrww>75/
{0157} Antibodies bound per cell (ABC) values were determined for the FOLRl-positive
tumor cell lines (KB, IGROVl, JEG3, and ) using anti-FOLRl-Phycoerythyn'n,
BD brite Beads, and flow cytometry and were shown to have different ABC values.
(Figure 2). Staining conditions were optimized for FOLRl so that the cell pellets prepared
from the FOLRl-positive tumor cell lines showed varying levels of staining intensity by
IHC. The KB cell pellet exhibited very strong (3+) homogeneous staining with high
intensity, the IGROVl cell pellet showed strong (3) staining, the JEG3 cell pellet showed
moderate (2-3) heterogeneous staining, while staining of the OVCAR3 cell pellet showed
low intensity (1—2) heterogeneous staining. The FOLRl staining intensity trends observed
from the cell pellets correspond to the reported ABC values, where KB cells exhibited the
highest ABC value of 1,700,000, IGROV—l cells exhibited the next highest ABC value of
0, JEG-3 exhibited a lower ABC value or 41,000 ABC, while OVCAR3 cells
-44_
showed the lowest ABC: value of 4,000. The staining results and respective ABt‘IZ vaiues are
iisted in the table below.
ABC values and respective staining results for huFOLRl on cell lines and respective cell pellets.
FQLR i
KB 1,709,000
EGROV} 260,000 3 heme
a'B'EGS 4i ,sus 2~3 hetero
UV’CARE E 4,000
Additional cell lines, including Capan-l, Jar, Hec—l-A, Hec—l—B, lshikawa, NCI H292, BT474EEI,
PA-l, OV—90, CaOv-4, CaOv—E, A2780, Ovcar-S, Ovcar—4, HCT—lS, 786-0, NCI H838, NCI H
522, NCl H2110, NCI H1734, NCI H228, and FU.OV-3 were tested and found to be FOLRl
positive but FOLRl sion levels and sensitivity to the anti-FOLRl immunoconjugate activity
varied. For reference es, cell lines having consistent FOLRl expression and ivity to
anti—FOLRI immunoconjugates are preferred.
{0168} Particularly important was that the lHC method was able to reliable ed FOLRl
expression in ovarian carcinomas and non-small cell lung cancer ) tissue s.
As shown in Figure 3, FOLRl expression could reliably be detected in ovarian carcinoma
and NSCLC samples scored 2 hetero to 3 homo. ABC values for these samples ranged from
approximately 41,000 for samples scored 2 hetero, to greater than 260,000 for samples
scored 3 homo. As shown in Figure 4, high staining intensity and mity of ng
was also observed in ovarian carcinomas, lung adenocarcinomas, and bronchioloalveloar
carcinomas. Furthermore, expression of FOLRI in NSCLC samples (Figure 5) and in
ovarian carcinomas (Figure 6) were further found to be predominantly zed to the
membrane in tissue samples. Expression was detected across multiple samples from the
same, as well as different tumor samples. Interestingly, none of the samples from
colorectal, breast, or small cell lung tumors were scored greater than 2 hetero.
In vivo efficacy ofhuMov19-PEG4Mal-DM4 and huMov19—SPDB-DM4 ates in
comparison with similar non-targeting conjugates in a KB xenograft model
FOLRl—targeting cleavable conjugate huMov19-SPDB—DM4 in comparison with
rgeting huC242—SPDB-DM4, and non-cleavable conjugate huMov19-PEG4-Mal-
DM4 in comparison with non—targeting —PEG4Mal-DM4 were tested using an
established xenograft model of KB cells (very high FOLRl expression, 3+ homozygous by
manual IHC) ted subcutaneous into SCID mice. Mice were randomized by body
weight into treatment groups and treated either singly (SPDB ates) on day 3 post cell
inoculation, or three times weekly on days 3, 10, and 17 post cell inoculation with 5 and 10
mg/kg of a conjugate, respectively. The median tumor volume of the different treatment
groups is plotted in Figure 7. The treatments with either huMov19—SPDB-DM4, or
huMov19-PEG4Mal-DM4 ed in a decrease in median tumor volume as compared to
the PBS control, while the treatments with either of the respective non-targeting conjugate
did not produce any significant effect.
Example 3
Dose-response anti—tumor activity of IMGN853 treatment in OVCAR-3 human n
carcinoma xenografts
{317%} The anti-tumor effect of IMGN853 was evaluated in an established subcutaneous
xenograft model of ovarian carcinoma. SCID mice were inoculated with 3 ovarian
carcinoma cells (1 x 107 cells/animal) injected subcutaneously into the right flank. When the
tumors d about 100 m3 in size (21 days after tumor cell inoculation), the mice were
randomly divided into four groups (6 animals per group). Mice were treated with a single
intravenous injection of IMGN853 at 1.2, 2.5 or 5.0 mg/kg. A control group of animals
received a single intravenous injection of PBS. Tumor growth was monitored by measuring
tumor size twice per week. Tumor size was calculated with the formula: length x width x
height x 1/2.
IMGN853 was highly active against 3 tumors (IHC score of 3 homozygous
using manual IHC methods) in terms of tumor growth inhibition (T/C = 0 %) at both the 2.5
and 5.0 mg/kg dose levels (Figure 8). There were complete tumor regressions (CR) in 6/6
mice treated with IMGN853 at 5.0 mg/kg. There were partial tumor regressions (PR) in 6/6
-46..
mice and CR in 4/6 mice d with IMGN853 at the 2.5 mg/kg dose level. 3 was
active at the 1.2 mg/kg dose level, resulting in a T/C of 18%, with 2/6 PR and 1/6 CR.
According to NCI standards the T/C values ranging from 10% to 42% are considered to be
active, T/C of less than 10% are considered to be highly active.
Example 4
Dose-response anti—tumor ty of IMGN853 treatment in IGROV-l human ovarian
carcinoma xenografts.
{017.2} The anti—tumor effect of IMGN853 was ted in an established subcutaneous
xenograft model of ovarian carcinoma. SCID mice were inoculated with IGROV-l ovarian
carcinoma cells (1 X 107 cells/animal) injected subcutaneously into the right flank. When the
tumors reached about 100 mm3 in size (7 days after tumor cell inoculation), the mice were
randomly divided into four groups (6 animals per group). Mice were treated with a single
intravenous injection of IMGN853 at 1.2, 2.5 or 5.0 mg/kg. A control group of animals
received a single intravenous injection of PBS. Tumor growth was monitored by measuring
tumor size twice per week. Tumor size was ated with the formula: length X width x
height X 1/2.
IMGN853 was highly active against IGROV-l tumors (IHC score of 3 homozygous
by manual methods) at the 2.5 and 5.0 mg/kg dose levels, resulting in T/C values of 5% for
both dose levels (Figure 9). There were partial tumor regressions in 5/6 and 6/6 mice in the
2.5 and 5.0 mg/kg groups, respectively. IMGN853 was inactive at the 1.2 mg/kg dose (T/C
= 47%).
Example 5
Dose-response anti-tumor activity of IMGN853 treatment in OV-90 human ovarian
oma xenografts.
The anti-tumor effect of IMGN853 was evaluated in an ished subcutaneous
xenograft model of ovarian carcinoma. SCID mice were inoculated with OV-90 ovarian
carcinoma cells (1 X 107 animal) injected aneously into the right flank. When
the tumors reached about 100 m3 in size (13 days after tumor cell inoculation), the mice
were randomly divided into four groups (6 animals per group). Mice were d with a
single intravenous injection of IMGN853 at 1.2, 2.5 or 5.0 mg/kg. A control group of
-47r
animals received a singie intravenous injection of PBS. A, control group of animals
received PBS administered intravenously a". the same schedule. Tumor growth was
monitored lay measuring tumor size twice per week. or size was calculated with the
formula: length x width x height X 1/3..
{M75} lMGNSSZS was active against OV~9C¥ tumors {ii-EC score of 3 lretero~homo by
manual methods) at the 2,5 and 5.0 rag/kg dose ievels, resulting in T/C values of 36 and.
18%.», respectively (Figure l0). ‘l‘wo s had partial, tumor regressions in the SiO trig/leg
the treatment groups. EMGNSSB was
group; there were no other tumor regressions in any of
inactive at the 1.2 mg/kg dose (T/C = 77%).
Exanqfieo
Dose-response anti-tumor activity of IMGN853 ent in SKOV-3 human n
carcinoma xenografts.
[0176} The anti-tumor effect of IMGN853 was evaluated in an established subcutaneous
xenograft model of ovarian carcinoma. SCID mice were inoculated with SKOV—3 ovarian
carcinoma cells (1 x 107 cells/animal) ed subcutaneously into the right flank. When the
tumors reached about 100 mm3 in size (26 days after tumor cell inoculation), the mice were
randomly divided into four groups (6 animals per group). Mice were treated with a single
intravenous injection of IMGN853 at 1.2, 2.5 or 5.0 mg/kg. A control group of animals
received a single intravenous injection of PBS. Tumor growth was monitored by measuring
tumor size twice per week. Tumor size was calculated with the formula: length X width X
height x 1/2.
lMGNSfiS was inactive against SKOV—B tumors (lllC score of 1—3 focal by manuai
methods) at all , with growth of ihlilGNiéSfi—treated tumors paraileling the PBS control
group (Figure ll). There was no data analysis performed; and the study was temiinated
early based on the inactivity or? lMGNSSCi in this model.
esponse antiutumor activity of llvltiiN853 treatment in KB human cervical
arcinoma xenografts.
{M78} The antiwtumor effect of lMGNSSES was evaluated in an established aneous
xeuograft cervical adenocarcinoma model. SCED mice were inoculated with KB cervical
,4gr
adenocarcinoma cells (1 X 107 cells/animal) injected aneously into the right flank.
When the tumors reached about 100 mm3 in size (7 days after tumor cell inoculation), the
mice were randomly divided into four groups (6 s per group). Mice were treated with
a single intravenous injection of IMGN853 at 1.0, 2.5 or 5.0 mg/kg. A control group of
animals ed a single intravenous injection of PBS. Tumor growth was monitored by
measuring tumor size twice per week. Tumor size was calculated with the formula: length X
width X height X 1/2.
IMGN853 was highly active against KB tumors in terms of tumor growth inhibition
(T/C = 0 %) at both the 2.5 and 5.0 mg/kg dose levels (Figure 12). Six of six mice in the 5.0
mg/kg and five of siX mice in the 2.5 mg/kg treatment group had CR5, and remained tumor-
free to the end of the study (day 120). The 1.0 mg/kg dose was active, resulting in a T/C of
37%, but there were no partial or complete regressions.
Example 8
lmmunohistochemical staining of FOLRl in formalin fixed paraffin embedded (FFPE)
samples— ted methods.
{0180} The IHC staining assay uses IVD class I reagents including the Novocastra FOLRl
antibody (Novocastra/Leica Cat # NCI-L-FRalpha, clone BN3.2) as the test article and the
Leica Bond RX automated r. Bound test or control article were detected by incubation
wéth the Leica Bond Refine detection system which includes a post primary reagent (rabbit
anti—mouse IgG), followed by a polyneer reagent (goat anti—rabbit polymer) and 3,3-
Diaminobenzidine tetrahydrochloride (DAB) gen. FFPE samples were d with
the specified concentration(s) of primary antibody (prepared by diluting in Leica diluent
FOLRl) as outlined below.
IHC Antibodies
wFolate Rec$8}'Kififig‘ZfiBQSEEQEE/Leica‘E‘éiQiiiicil‘fffiiigifiii?
Test article” Lot 159506), murine, clone BN3.2, liquid concentrate: 75
ug/mL
IgGl an Coulter Cat.# 6602872, LotsZS7SPSO4-23
Control article” and 2S7SPSO4-26) stock concentrationzl mg/mL, murine,
clone 2T8—2F5
_49“
FFPE Assay Method using Leica Bond RX
Amman Time
minutes
1333515112 ?“
-— w:Perokide(Refine
mdooenous Peiexjidasc Blank kit component)m5m1nuteswwm
fest Arti‘cie F:0LR1 at 1.9 ug/mL1n Leica 15 minutesuwm
diluent
Winn“‘“"llw"mm““V“;N‘m‘mmmmary,, Reag€n¥kRefine‘ “““““““““““““
‘ E
kit)
POWEW E'Iriiiiiitégmj
lVIlXedDAB kit)“ W10mlnutesmm:
:(JouriterstammwHematoxylm (Refine kit) "5mhiutes WM
{$181} All stained samples were evaluated and scored. Control samples were first
evaluated followed by test samples (whole sections and individual cores from the TMAs).
For each tumor tissue or cell pellet evaluated, a description of the staining intensity and
respective proportion of tumor cells stained was reported. Membrane associated staining
was recorded for every sample. When duplicate scores were evaluated from one patient,
only the higher score was included in the analysis. If the score described only cytoplasmic
staining then the final score was reported as zero (0). Intensity and uniformity were given to
each sample as described in the table outlined below. Staining ity and distribution
patterns were scored relative to control IgG staining pecific). Intensity was scored on
t=== moderate and 3 E strong) and distrébution
a scale of 0 to 3 (0 = no staining, 1 = weak, 2
was scored as focal (<25% of cells d), heterogeneous (25-75% of cells stained) and
homogeneous (>75% of cells stained). In normal tissue, only the defined substructures were
ted when calculating intensity and proportion.
IHC Scoring System ting of Intensity and Uniformity Scales
Intensrty (brlghtness of stain)
f intensity wed Intens1ty Category Ity Reported
‘ l
O Negatlve
{H Very Weak
intensity (brivhmess QfSEain)
RRoak to lviodercrte
2 Moderate
2—3 Moderateto Strong
E9182} FFPE tumor samples were derived from tumor micro arrays, as well as human tissue
blocks from seven ent tumors, as outlined below.
FFPE Test Samples: TMAs
Anatomic Site Number of Total # of
Cores per Patients
Patient
E Kidney Pantomics KIC1501 R-KID- 2 69
122711-1 1
Pantomics i LUC1501 EP-T-ARR-LNG— E 2 70
122711 1 E a
“‘“EW” W ‘ 777777
Tristar 69571059/TA1249 E-PTARR-OVA- E
‘ E122711 1 :
-5 RR-OVA- E
122111 1 a E
OVClSOl EP-T—ARR—OVA- E
12271 l- l
...... WE.” “WWW...“
...m E;...........»....
6957109l/TA1322 E-PT-ARR-OVA-
E010912- l
l ......"-—_
I .......«......“
,, m““W
E Uterus (Endo— Pantomics EMClSOl PT-ARR-EME-
Emetrium) _WEWWMMM1227ll—l..
+._m“......“.....
Various Pantomics MTUZESTW P—T-ARR—
E I 12271l—mlVVVVVVVVVV
w...;..;.;(._;«.‘........... ...7...7....r.r....n..»““““an.muu...................._
«SE,
FFPE Test Samples: Whole Sections
.“xx“.“wunn“NV“...VVVVVV V.VVWVV_V_V__.“\“»““
Organ iCode Source Diagnosis (per Source Documentation)
Ovary Tanflmijflu 1 Unknown endometroid adenocarcinoma
,V;;,,,,JV bJ genex g endometrord adenocarcinoma
,;,,,,;.;V,,, LN CHTN arcinoma, mixed with features of endomehod
serous and clear
W... VVVVVVVVVVVV“Wm
4 adenocarcmoma, high grade w/ mixed papillary, serous,
g endometrloidandclear cell areas 5
i; serous papillaryadenocarcinoma
Vme‘mmmcm“VVVVVWMM”...“me
SBI‘OUS adenocarcinoma
VVVVVrVr.r.r_r_““»»»‘“‘mme.
Proteogenex +.,,,,,,,,,
....................mm
‘ genex
serous papillary adenocarcinoma 1
I1 VVVVVVVVVVVVVV.VVVsccVVVVVtcccccccccccVVVVV.aaass.......5cccccrr..............4
adenocarcmoma, poorly entiated
adenocarcinoma, acinar welldifferentiatedwith
bronchioloalveolar featuresa““Wuug.s........VVVVVVVV.VVVVVVVVV—r..““‘»»““““ml
adenocarcmoma, mucinous features
adenocarcinoma
adenocarcinoma
l «A.
adenocarcinoma (bronchioloalveolar) carcinoma
adenocarcmoma
adenocarcinoma, moderately differentiated, with clear
3 cell features
: l
a t
< t
i ..s...‘.V..VVVVVVVVVVVVVVV.V~‘ccccc‘cceec.ccccVVVVaaaa....a......ss_..rr..rrrr‘.............t..VVVVVVVV_____Vv;;
Cells (tumor cells or transfected cells) were formalin fixed and paraffin embedded
(FFPE). FFPE cell pellet samples shown to exhibit varying ranges of FOLRI sion by
flow cytometry and normal human tissues were used in this study to characterize ve
and negative controls and for is of specificity. The cell pellets exhibiting varying
levels of FOLRl and the respective scores are reported below. There is a poor correlation
between staining scores and the respective FOLRl expression levels (antibodies bound per
cell, ABC, determined by calibrated flow cytometry) in the cell pellets. For example a
score of 1—3 hetero is given for the SW620 and l exhibiting 40,098 and 565,481
ABC values, respectively. Additionally, Hela cells showing an ABC value of 1.5 million
resulted in a score of 2-3 hetero while 300.19/FR1 exhibiting 830,003 ABC returned a
higher score of 3 homo.
Final Scores for Celi Pellets at a Test e Concentration of 1.9 ug/mL
§ {39.31 Line aABC Value
rrrrrr “1:“Staining Score »“““
Wu““u....n~“~“vw_»__rrrrrrrrrr w—v—_ §
3 83137621} 411,888 I-3 hetero
T471) l -2 hetero
—(nun........“WW“.“way.“u.»»»‘ “.Tmfié
Wuuuu.«....VVwwwww«Whe‘““»»»“‘Wu—— _
1URUV 1 L565,481 1-3 hetero g
30019/ FRl 830003 3homo E
HBEA E1 500587 tero
KB "14,000,000 3homo
aThe reported ABC Valueis anaverageofant1bod1es boundpercell1n thecellpopulation and“
was determined as follows: a concentration of 1.0 X 108M of anti—FOLRl ~PE (1 :1) was used
ine ABC values on the respective cell line using flow cytometry s and Quantibrite
TM Beads (BD Biosciences).
- The flow cytometry histograms represent the distrébution of cells versus the number
of anti-FOLRl bound per cell (FOLRl expression level). Both the histograms and
respective IHC staining results indicate that each of these cells lines contain a
heterogeneous tion of cells having a broad range of FOLRl expression. The
exception is the 300.19/FR1 cell line showing botl: a m flow cytometry histogram and
IHC staining score. This data suggests that cell lines each expressing a more m level
of FOLRl may provide a better correlation between ABC values and respective staining
scores. Although the assay demonstrated positive staining in all FOLRl-positive cell pellet
controls, there is a poor ation between staining scores and the respective FOLRl
expression levels from most of these cell pellets. Therefore, cell pellets from this group
could not be identified as high-, medium—, and low-expressing controls. Representative
photographs and rams depictirzg FOLRl expression in cell lines by IHC and flow
cytometry are shown in FIGURE 13.
{111353 To determine assay conditions, a range of dilutions of test and control article were
tested to select conditions that exhibit an appropriate level of sensitivity. Experiments were
-53..
performed on a panel of FFPE samples including FOLRl-positive cell s and a TMA
consisting of FOLRl positive and negative normal tissues (adrenal (cortex/medulla), breast
(ducts and s/connective ), fallopian tube (surface epithelium/muscle wall),
kidney (tubules/ glomeruli), lung (type I/Il pneumocytes/interalveolar connective tissues),
pancreas (ducts/islets of Langerhans), salivary gland (ducts/stroma), skin (eccrine
/epidermis), stomach (surface epithelium/submucosa)), and whole sections of tumor
s (10 ovarian tumor samples and 10 lung tumor samples). Each sample was stained
with a serial dilution of test article concentrations (0.25, 0.5, 0.9, 1.9, 3.8, and 7.5 ug/mL) or
control article concentration of 1.9 ug/mL or 9.8 ug/mL. The relative staining intensities
for each dilution were compared for each sample to identify the optimal dilution. The
criteria for optimal dilution was a dilution which 1) caused no background staining in
samples stained with isotype control 2) caused no ng in negative tissue controls stained
with test article and 3) differentiated between varying levels of membrane-associated
FOLRl expression among test samples representing the indication of interest (ovarian
tumor, endometrial tumor, NSCLC tumor, and kidney tumor FFPE tissues). Of the five
dilutions of test article evaluated, the tration of 1.9 ug/mL showed the best dynamic
automated protocols (Bake and Dewax
range in staining results using the Leica Bond RX
Protocol, HIER using the ER2 for 20 minutes protocol, and the staining protocol IHC F-
With Extra Rinses).
Example 9
Identification and terization of controls that characterize the dynamic range of the assayautomated
ng methods
Quality controls: Human normal salivary gland, lung and pancreas were identified
as positive tissue ls to be ed in each assay to verify that the staining procedure
performed as expected. Human normal esophagus was identified as a negative control.
These controls were characterized as follows: in order to establish ls which cover the
dynamic range of the assay, a tissue microarray (TMA) consisting of several FOLRl
ve and negative normal tissue s expected to exhibit the dynamic range of the
assay was used as an assay verification control during the optimization and validation
phases. Four normal tissues with identified structures in this TMA were identified as
suitable assay controls as follows: respiratory epithelium of normal human lung (score of 2
homo); ducts of normal human pancreas (score of " homo apical); intercalated ducts of
normal human salivary gland {score of l~2 hetero); and normal human esophagus (score of
0) Over a total of 5; assay runs the identified le assay controls from this TMA gave
identical results. These results indicate that the selected ls give consistent results and
span the dynamic range of the assay.
ures in Normal ’if'issues identified as Controls that Span the Dynamic Range of the
Assay
ENtirin;E iii}Structure StainingScoremiim Staining Scorefiest‘i
E'G:gen :
(controi article) article)
EEsophagiix kill stmctnre; 0 ive) Efiiiicganm;
livaryGland lotei‘calated ducts NEW0 (negative) WE i~2 here
i WWW
RespiratoryEpitheimvo‘iElhomo
NPantria:---~WEDncts (E) {negati“3)meMMwE”honiowapitai
[\rpicaE staining is definedas polarized nonuinfmm membrane staining
e 10
Perfom‘iance analysis oftite automated staining method.
{$187} The intended use of this assay is to specifically detect FOLRl reproducibly and with
the appropriate sensitivity to differentiate varying levels and varying mity of
membrane—associated FOLRI expression (optimal dynamic range) in ovarian, endometrial,
NSCLC, and kidney FFPE tumor tissues. Therefore, specificity, reproducibility, and
sensitivity were considered as mance ia.
The specificity and sensitivity of the study assay was evaluated by comparison of
normal tissue ng with the study assay to previously reported results. Staining s
frorn this study were compared with corresponding ng results from Scorer et al 2010
(A Fall Immunohistochemical Evaluation of a Novel Monoclonal Antibody to Folate
or alpha. The Novocastra Journal of Histopathology, REAGENTS: 2010(3):8-12,
describing the same antibody clone BN3.2) with FFPE normal tissue and from the Tissue
Cross Reactivity (TCR) study using IMGN853 (huMovl9 (M9E46A) antibody) on fresh.
frozen normal tissue (ImmunoGen Report lMH28—OO3). Comparison of the staining results
from each method indicate that the three assays showed generally similar normal tissue
staining profiles with differing relative sensitivities, with the Scorer assay being least
sensitive, the study assay (IMH28-011) having intermediate sensitivity, and the TCR study
method being the most sensitive. Some structures showed positive staining in the two more
ive methods (study assay and TCR assay) only. There were no examples of positive
staining in the least ive assay used by Scorer that were not also positive in the study
assay and TCR method. These results demonstrate that the specificity and sensitivity of the
study assay is appropriate for the evaluation of FOLRl sion in normal tissues.
The specificity and sensitivity of the study assay was further characterized by
staining and evaluating a panel of tumor TMAs consisting of ovarian, endometrial, NSCLC,
and kidney tumors (a sample set representative of the assay’s intended clinical use).
Positive staining was tently localized to the tumor tissue with normal adjacent tissue
components including , blood vessels, lymphocytes and normal organ tissue staining
negative or positive as expected. For each subtype of either ovarian carcinoma or NSCLC,
the distribution of staining scores among TMAs from the different vendors showed a similar
distribution of scores ting this method is not sensitive to various fixation and
processing conditions. Because the distribution patterns were similar among the TMAS, the
data from the different arrays was combined and scores were categorized. A summary of
these scores for tumor subtypes that contained 20 or more samples per subtype are listed in
the following tables. As summarized in these tables, a dynamic range of scores is noted for
each tumor type and indicates that this assay shows the appropriate sensitivity to distinguish
varying levels and varying uniformity of membrane—associated FOLRl expression in
ovarian, endometrial, NSCLC, and kidney FFPE tumor tissues. Representative photos of
serous n, endometroid ovarian, NSCLC, endometrial carcinoma, and renal clear cell
carcinoma are ed in s 14-18. Additional representatitive photos useful, for
example, in a staining guide or diagnostic kit, are shown in Figures 23—25. These studies
indicate the assay is specific and has the appropriate sensitivity for use as a diagnostic or
companion diagnostic reagent.
Summary of Staining Scores for Predominant es of Ovarian Tumors
Subg"“p““;""" “E‘Silifiglvumser
1 We)
~56-
Eff} RS
l)Focal staining patterns were excluded
Summary of Staining Scores for NSCLC Tumors
Sample Number
§Tota1 23 722
hetero"A
heteroa =
L Fugitiww
iAdeho- A11b s 47 20
icarcmoma $100) (25) . (58)
Spec1fied 7
Bronchiolo- ~~
(100)(29)
;alveolar ! i (71)
w 7777777777 gm“...”EmrrrrrrrrrrL “71;
Squamous All 74 l
100 1 5
oma i in )5;()W: ( )
) Focal
stainlng patterns were excluded
All adenocarcinoma s were included except the specified bronchioloalveolar carcinoma samples
_ 57
Summary of ng Scores for Adenocarcinoma ofthe Endometrium and Clear Cell
Tumors of the Kidney
WW, “uh...“‘e
Tumor/Subflpe i Sample Number
1:%)
i Exec“..‘.\w.m.n.}..~m......m..V“w.wV__vmv.r.““““ee» m“ i mm...“tT."nmfimmzzzrfiteeee
i a Total E 23 _2 2 1 1-3 focal
k 3 Any Negative
i E heteroa heteroa “ : Positivity
l : ‘
We.“a»... .w...wmvw.‘wr .ze..““‘““»“““
._._.......... wfivw
eeeeecee‘“
i Endometnum/ 58 5 3 E 30 10 40 18
i Aden0_ u..u“~§un~~finwwwmea »»»»»“““““
E un“......u“ui,u.“w“vVV__-;;;=A.x»§\»»\\\.“W (100) (9) 40) E (52) (69) (31)
carcinoma a
{gvvvvvv,_ w ,,,,,, t
3 Cell (100) (0) E (68) (18) (85) (15)
WWW “WW“
FoEai“;i;1‘Hng§aEEfi wereieileiiiied
The precision of the study assay was igated by evaluating intra—run and inter-
run reproducibility of the assay using three FFPE tumor tissue samples of ovarian, NSCLC,
or kidney tumor where each sample exhibits either a high, medium, or low score. For intra~
run reproducibility, nine slides each containing a section of lung, ovarian, and renal tumor
were placed at nine random locations on the Leica Bond RX. For inter-run reproducibility,
three slides containing sections from the same sample were d on three different days.
All slides from both intra-run and inter—run reproducibility experiments were evaluated and
showed equivalent staining results for each respective sample: lung tumor (high: 3 homo),
ovarian tumor (medium: 2 hetero), and renal tumor (low: 1-2 hetero). This data
demonstrated ucibility across tissue types with low, medium and high level of
expression.
Example 1 l
A FOLRl expression score ofZ 2 geneous by IHC is a patient selection criterion for
treatment with IMGN853.
The levels of FOLRl-expression in tumor cell lines were determined using the an
antibody-l)E conjugate 4-PE) and the QuantiBRlTE system. Three ovarian
carcinoma cell lines (Igrov—l, Skov-3 and Ovear-3), a choriocarcinoma cell line leg-3 and a
cervical carcinoma cell line KB were included in the study. In order to obtain reliable ABC
values, the binding experiments with an antibody—PE conjugate should be performed at a
-58—
saturating concentration (concentration, at which all available binding sites are occupied by
the conjugate). To determine such concentration for the -PE conjugate, we
performed binding experiments on a panel of FOLRl—positive cell lines with various
FOLRl expression. The cells were incubated with a wide concentration, range of FRl—24-PE
conjugate for two hours on ice, washed with FACS buffer (PBS with 1% BSA), fixed with
1% formaldehyde in PBS and analyzed on a FACSCalibur flow cytometer. At a
concentration of 1x10'8 M the conjugate saturated cell e binding sites on all tested cell
lines lgrov-l, Jeg-3, Skov-3, Ovcar-3, and KB. In subsequent binding ABC-experiments
-PE conjugate was used at concentration of 1x10"8 M. Each sample was analyzed in
triplicates; several independent experéments were performed on each cell line. The highest
expression was found on KB cells with the approximate ABC value of 4,000,000i300,000,
followed by Igrov-l and Jeg-3 cell lines with the ABC values of 400,000i85,000 and
150,000i75,000, respectively. Two cell lines, Skov—3 and Ovcar—3, had low FOLRl
expression, 20,000i10,000 and 7,00014,000 ABC, respectively. A cant experimentto-experément
variation of ABC values was observed for Jeg—3 cells, where the ABC—values
varied from 40,000 to 300,000. This varéability likely reflected some biological properties
of the cell line rather than the assay ility, since ABC values obtained for the other
analyzed cell lines were much less variable (see table below).
“Celi‘line l
i ABC Experiment--toexPehEIehi‘QQIii
{Mean i ‘53» it)” The highest ABC The lowest ABC
, ,1
i 1 ered registered
KB 00 3:300000,4 4,500,000““ WW3800000W
,, ‘i‘
Igrov-l % 400,000j:85000 5 480,000 0
Jeg-3 150,000 i:75,000, 14 imwwm 40w000w
Skov—3“ r
“3: 10,000 2m 10,OOOWWWWa
SDStandarddev1ation n- number ofindependent experiments
ABC values were determined by a FACS based assay with FR1-24 PE—labeled antibody and
QuantiBRITE system. Mear: i Standard Deviation (SD) was calculated for independent
experiments.
E8192} Potency and specificity of 1MN853wwas ed against FOLRE ~positive teii
lines with a wide range of FOUR} expression (the ABC values of the cell lines are provided
above) in addition FOL-R1negative ceiii lines Namaiwa and SWZ were included in the
experiments. IMGN853 was highly cytotoxic against cells with high FOLRl expression KB
(4,000,000i300,000 ABC), Igrov—l (400,000zt85,000 ABC) and Jeg—3 (150900171000
ABC), with the ICso values of 0.10i0.01 nM, 0.50i0.07 nM and 1.00i0.05 nM,
respectively. The cell-killing activity against all three cell lines was FOLRl-dependent,
since an excess of unmodified 9 (M9346A) antibody (0.5 uM) ly decreased
potency of the conjugate to the typical non-specific levels (from 10 to 20~fold). 1MGN853
was only marginally active against the low FOLRl expressors Skov-3 and Ovcar-3 cells
(20,000::10,000 and 7,000i4,000 ABC, tively), and against FOLRl-negative cells
Namalwa and SW2, with the IC50 values greater than 2 nM. The cytotoxic activity of
IMGN853 against these cell lines was low and not FOLRl-dependent, as blocking with
huMovl9 (M9346A) did not affect it. See Figures 19 and 20.
FFPE samples prepared from mouse aft tumor models were evaluated for
FOLRl positivity using the zed and validated assay described above. No staining
was seen in tumor cells of any xenograft samples stained with control article. FFPE mouse
xenograft tissues derived from the ing cell lines showed the following staining
patterns: lgrov-l, KB, and 110 showed neous staining patterns with level 3
intensity; Ishikawa and Ovcar 3 showed heterogeneous staining patterns with level 3
intensity; LXFA737 showed homogeneous staining patterns with level 2 ity; OV-90
showed heterogenous patterns with level 2 intensity; and SKOV3 was negative.
Representative photos of tumor xenografts are provided in Figures 21 and 22.
-60—
E\ParentalN Disease‘ EFlnalbcore "SEEMS;
Cell Line E Indication E Category
or Tumor E
IGROV—I EOvarian cancerE I —3 homo E 3 homo
E l-3homo 7
E E1-3 homo
Ishikawaum‘EndometnumE2-3hetero 7777777777 E3hetero
cancer 1 2‘hetero/3
focal
E E 2 hetero/3 focal
i E2 hetero/3 focal , ,
“ “E‘éFVmical
E 3 homo Ehomo
cancer E 3WW
mm we 1'2 hdfiiB'Ziiiiii........
2 homo
NCI— 2—3 homo” EE‘homo
H”Ovarian
OV-90 cancer 1-2 hetero 3:16:30
""""""WghetemE
OVCAR3 63mm cancer 1333%
hetero
“ E
Ovarian cancer Negatlve Negat‘Eémi
Negatlve i
A staining threshold (22 heterogeneous) requires both a minimal level of expression
(staining ity) and m distribution of staining ntage of tumor cells
expressing . Pre-clinical data es justification for this threshold in ovarian
carcinoma. Mouse xenograft tumor samples with IHC scores of 2 2 heterogeneous exhibit
sensitivity to IMGN 853 in vivo. FFPE samples prepared from mouse xenograft ovarian
tumor models were evaluated for FOLRl positivity using the optimized and validated assay
described above. Two n carcinoma xenograft models OVCAR-3, and IGROV— I
showed a heterogeneous or homogeneous staining pattern with level 3 ity. The
xenograft model derived from OV-9O ovarian carcinoma cells showed a heterogeneous
ng pattern with level 2 intensity; the Skov-3 ovarian carcinoma model was FOLRI-
negative. IMGN853 was highly active in the two ovarian models with level 3 FOLRI
intensity and active in the OV—9O model with level 2 FOLRI intensity. No activity was
observed in the SKOV-3 model. Xenograft models were also evaluated for other diseseas
~61—
indications including lung, endometrium, and cervical tumors and, although correlations
were ed between activity and FOLRl ng scores, additional samples must be
tested.
{@195} The sensitivity of ovarian tumor aft models to IMGN853 versus the Eevei of
FOLRI expression
Xenograft In vivo activity (5 mg/kg of Intensity score, distribution
IMGN853, single dose) w,
Mew...“ ,,
OVCAR3 Highly active E
- 3 heterogeneous E
“mmmm... ,, u...mummw{momenmtme
E IGROV-l Highly active E 3 homogeneous
OV-90 Active 2 heterogeneous
E SKOV-3 s Inactive Negative
E = :
The sensitivity of other tumor xenograft models to IMGN853 versus the level of FOLRl expression
In vivo activity (5 Eng/kg 0f Intensity score, E
IMGN853, single dose) distribution E
Highly active 3 homogeneous
lshikawa Eindometrium Inactive 2 homogeneous E
E: ooooo WWW
KB Eilervical Highly active 3 homogeneous E
:“WWMMMWWHW
All publications, patents, patent applications, intemet sites, and accession
numbers/database sequences (including both polynucleotide and polypeptide ces)
cited herein are hereby orated by reference in their entirety for all purposes to the
same extent as if each individual publication, patent, patent application, et site, or
accession number/database sequence were specifically and individually indicated to be so
incorporated by reference.
-
SEQEENCES
SEQ ID NQt’i — huxtnan foiate mr 1
MAQRLMTI‘QLLLLLV“WAX/WGEESAQTR{AWAR'I‘ELLNVCMNAKBHKEKPGPEZEQKLHEQCR
PWRKNACCS’ENTSQBAHKD‘VSYLYRFNWNHCGEMAPACKRHFIQDTCLYECSPNE...GE’Wifi
QQVDQSWRKERVLNVPLCKEEIXIEQWWEDCRTSYTCKSNWHKGWNW/"1‘86ENKCAVGA
ACQPFHFY}???PTVLC’NEIWTHSYKVSNYSR‘Ci‘SG-KCEQMWFDRKQGNPNEEVAKE1‘Yl’fL/XAl‘s/i
SGAGPWAA‘WPF1,,I,,S’3L,.AE.,MILLWLLS
SEQ ID N02 ~ human fi‘fiate receptor 1 nudeic acid Sequsnce
atggctcagcggatgacaacacagc;tgGigdeem:tagtgigggtggctgtagtaggggaggctcagacaaggattgcatgggccaggact
gagcttcicaaigtctgcatgaacgccaagcaccacaaggaaaageGag,gccccgaggacaagttgcatgagcagtgEcgamctggagga
agaatgectge‘igttctavmaaaaccagecaggaagcccataaggatgtttfict3cata‘iatagaficaactggaaccactgtggagagatggca.
cctgcctgcaaacggcamcatcc21ggacacctgcctctacgagtgctcccacaacfiggggccctggatccagcaggtggatcagagctgg
cgcaaagagcgggtactgaacgtgcccctgigcaaagaggactgtgagcaatggtgggaagafigtatgcacc‘tcctacacctgcaagagcaa
ctggcacaagggctggaactggacttcagggtttaacaagtgcgcagigggagctgcctgccaacctficcatfictacficcccacacccactg
caatgaaatctggactcacit.etacaaggtcagcaactacagccgagg{Iagtggccgctgcatccagatgtggficgacccagccca
gggcaacaccaatgaggaggtggcgaggm:iatgctgcagccatgagtggggctgggccctgggcagcctggcc{itcctgcttagcctgg
ccciaatgctgctgtggctgctcagc
SEQ 11} N03 — huMOViQ VHC
QVQLVQSGAE‘VVKPGASVKESCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYDGDTFY
NQKFQGKA‘E‘LTVDKSSNTAHMELLSLXIT‘SEDEAVYYCTRYDGSKAMDYWC:QG'I‘TVTVSS
SEQ 113N024 ~ huMevw VLCV} .00
DEVLTQSPLSLAVSLGQFAHSCKASQSVSPA Ts’l‘S LMH'WYHQKPGQQPRLLIYRASNLEA(3V
PDRFSGSGSKTDETLN 3 SP VELA'EEEILFAxtXT‘x’YCQQSREYPYTFGGGI‘KJLLEEIKR
SEQ ID NOIS ~ huMQv19 O
DI V1.30:8 3?1.;S’LAVSLGQPAHSCKASQSVSFAG’E‘SLMHWYHQKPGQQPRIZJiEJYKASNLEAGV
PDRFSGSGSK3715)FTLHSPVEAEDAATYYCQQSREY}?YI'FGGGTKLEEKR
A global biosciencc nonprofit
organization dedicated to biological
standards and biodiversity
IP, Licensingiand-Serviccs
10801 University Boulevard
-2209 USA
Mammals, ngim'azo 1
Telephone: (800) 638—6597
facsimile: (703)334—2932
Internet: hrrpzjlwwwmtoaorg
min-Wm“
mwwmmawW'tmmw
gs»sexesemsamxwwwwswsiswiuessua-memmmsmmwm:_';‘m\wtt\3\v;§s;\§saatmmemwmOF DEPOSIT
BUDAPEST RESTRICTED CERTIFICATEINTERNATIONALRECOGNITION OF
BUDAPEST TREATY ON THE OF PATENT URE
FOR THEPURPOSES
THE DEPOSIT OF MICROORGANISMSINTERNATIONAL FORM
TO. RULE 7.3
‘ DEPOSIT ISSUED PURSUANT
RECEIPT IN THE CASE OF AN ORIGINAL 10.2
ISSUED PURSUANT TO RULE
AND lTY STATEMENT
in connection
received your deposit of seeds/Strain(s)lstrain'(s)
Coilection (ATCC®) has
The American Type Culture is provided to fulfill Patent Officerequirements.
The foiloWing infonnation
with the filing of an application for .
Ms. Olga Ab
lmmunoGen. inc.
830 Winter Street
Waltharn, MA 02451—1477
Gen, inc.
Deposited on Behalf of:
by theATCC®2 April 07, 2010
Date of Receipt of seeds/strain(s)
.lQLQEéfiflspeifiwflQfiiflfléSIRE}; Quantity Received:
identification Reference byDegositor‘. ‘25 vials
PTA-10772
vials
recombinant plasmid DNA, phMov19H6v1.QCTK PTA-10773
recombinant plasmid DNA, phMov‘i-QLCV‘LO
that:
The ATCC® understands to infringe-the
either express or implied.
does not grant ATCC® a license, either express or
1. The deposit of these seeds/strain(s) to others does not grant them a license,
of these seeds/straws)
, and our release
implied. to infringethe patent.
it shall- be your sibility
term of the ,
die-or be destroyed during the-effective for distribution for
2. if the t should: to supply a sufficient quantity
it is also your sibility most
to replace it with viable material.
or 5 years following-the
the material for 30 years
will distribute; and in c‘ountriesrare signatory
the deposit'ter-m. ATCC® United'States and many other
whichever'is longer. The
recent request for the t,
to the Budapest Treaty. not to
e-time service ,
of a U.S. Patent, the ATC
instructed by the
Prior to the ce thereto or to their deposit except as and-
seeds/straini‘s) or any information relating to release the seeds/strain(s)
distribute these issues we are responsible for the
office. After relevant patent We will inform you of requests
depositor or relevant patent without any restrictions.
for distribution to the public
they will be made available of deposit.
strain(s) for 30 yearsfrom date
-— WWmvcgom~MV¢§£§\9¢.§§\_)\-§\VK€A\\§§h\%§$§r§x§wfi§§y§i§i¢
WQfiskwx‘WWWWW—W Doc-1D: 20127
Revision: 2
Effective Data? 10/13/2909
A global bioscience nonprofit
.'\' f: . E organization dedicated to gical
“ stnndards and biodiversity
IP, Licensing and'Services
10301 University Boulevard
Mamassu. Virginia 20'] 10—2209
Telephone: (800) 638-6597
Facsimile: (703) 334-2937.
Internet: htth/wwwmccnrg
§§§gficg§$§qmfimwxwg§§z§m9mwwfigpwwwcgjwmmmmymw,xwgwwmxgwfiwéggédfiiawmwww
seeds/strain(‘s)lwere viable
2010 and on that date, the
The deposit was tested Agril 201 Manassas, VA, USA
American Type Culture Collection (ATCC®),
international Depository Authority:
ity to represent ATCCG).
Signature of person having
i' mgiunyngmd hymn.
o-ATC‘.
mm=lallhl Flam-klhhlun,
LntF-d mam/innit , 0W5“WW,“
'rfiv‘i‘i‘il‘u'lnmzwuhmnoalcmg. o-US
manual]: 155in men- Agrii 23: 2010
,~»_»w .V. ....
Date
ATCC® Patent Depository
cc: Eric Steffe
2921 .0020000;
Ref; Docket or Case. No;
Wmm-va-WMAWWWW“\M\WMWW“\V°~VKW‘° ,_
Doc D: 20127
Revision: 2
a Date: 10/13/2099
A global ence nonprofit
organization dedicated to biological
standards andrbiodiverslty
lP, Licensing and‘Services
10801 University Boulevard.
Manassas,.Virginia.201‘l0—2209 USA
Telephone: (800) 638-6597
Facsimile: (703) 334-2932
lnte'rnet: http:JIwww.atcc;org
1:«coax{Q‘SSKMQ53‘§3§f§t§m.<,«vgossxflex:§\ww§<wififi§§xt§s&&$§a-WK§§'<§~W‘S\W\MW(&.\Yfi\$tv§m¢zg§wx\m\§3s;: §sxs§§xw§m~gvz§otwWpfismmwwsPamemesmmwefi
BUDAPEST RESTRICTED CERTIFICATE OF DEPOSIT
BUDAPEST TREATY E INTERNATIONAL RECOGNITION
PURPOSES OF PATENT PROCEDURE
THE DEPOSIT OF MICROORGANISMS FOR'THE
INTERNATIONAL FORM
ISSUED NT TO RULE 7.3
RECEIPT IN THE CASE OF'AN ORIGINAL DEPOSIT
PURSUANT TO RU LE 10.2
AND VIABILITY STATEMENT ISSUED
received your deposit of seeds/strain(s)/strain(s) in connection
The American Type Culture Collection (ATCC®) has information is provided to fulfill Patent Office requirements.
With the filing of an application for patent The following
Ms. Olga Ab
Gen. Inc.
830 Winter Street
Waltham, MA 02451—1477
Deposited on Behalf of: immunoGenl inc.
Date of Receipt of seeds/strain(s) by the ATCC®: April 07: 2010
ty ed:
Lgenficatiolfiefergme..b'y Dggtgsitor: ATCC ®Patent Deg}sit Designation;
PTA-10774 25 vials
Recombinant plasmid DNA, phMov19LCv‘l.6'
PTA-10775 2'5 vials
Recombinant d DNA, p'hF_R1-21HC
PTA-10776 2‘5 vials
Recombinant d DNA, phFRT] -21 LC
The ATCC® understands that:
to ge the
rant ATCC® a license, either express or implied,
i. The deposit of these seeds/strain(s9 does not Q
s) to others does not grant them a license, either express or patent, and our release of these seeds/strain(
implied, to infringe the patent.
be your
the effectiveterm of the patent, it-shall responsibility
2. If the deposit should die or be destroyed during sufficientquantity for distribution for
to replace it‘ with viable material; it is also your responsibility to supply a
years following the most
and maintain the material for 30 years or
the deposit term. ATCC® will distribute other countries are signatory
is longer. The United States and many
resent reqUest for the deposit, whichever
to the Budapest Treaty.
not to
the ATCC® agrees in consideration for a one-time service charge,
Prior to the issuance of a US. Patent, instructed by the
distribute these strain(s) or any information relating thereto or to their deposit except as
to release the seeds/strain(s) and
depositor or relevant patent office. After relevant patent issues we are responsible
will inform you of ts for the
the public without any restrictions. We
they will be made ble for distribution to
seeds/strain(s) for 30 years from date of t.
youri‘m‘ivzswsfiivixfivg.
ammwmnmmuwwmw.Wowns-MWmessikxwmx’s:eawm<«W~‘-®¥ewmfi“fiDoc ID: 20127
Revision:.-2
Effective Date; 101132009
A global ence nonprofit
organization dedicated to biological
standards and biodiversity
iP. Licensing and es
10801 University Boulevard
Manassas, Virginia 20110-2299 USA
Telephone: (800) 638-6597
Facsimile: (703) 334-2932
Internet: [iwww.aicc.org
mm-szxwmmmmuumwmwmmvmmwmmmwwfitxmwKwiflwqhfiWmawfiummmmmmmwmmwm
The deposit‘was tested Agril 23, 2010 and on thatdate, the seeds/strain(,s) were viable
international Depository Authority: American Type Culture Collection (ATCC®), Manessas. VA, USA
Signature of person having authority to represent ATCC®:
Digiuliy sign-d by Latin
t" Ramakrkhnan
" arugula Ronniqishmmva‘m:
110445 ‘ilci m6~04w
._e, Agfii26,2010
ATCC® Patent Depository Date
cc: Eric Steffe
Ref: Docket or Case No: 29210020000;
.wtwmmmwm-”mumummxw.“Wnaw‘me-muwurWuano.w+—emw~gmmgsywmfidemossmmxxg‘x'figiwg‘gx‘ m’j'gv' g‘mwm'a
Due in: 20127
- Envision: 2
Effective Date: 10/13/2003
—67-
Claims (47)
1. A method of identifying a tumor as sensitive to treatment the method comprising: 1 (FOLRl) antibody or antigen binding fragment thereof, tissue sample obtained from the (a) ing the level of FOLRl expression in a tumor wherein the measuring comprises the use of a detection method that tumor, distinguishes between ng intensity and staining uniformity in a FOLRl- and staining uniformity in expressing cancer sample as compared to staining intensity one or more nce samples; tissue sample; and (b) determining a FOLRl staining intensity score for the tumor reference (c) comparing the FOLRl staining intensity score ined in step (b) to a value determined by measuring FOLRl protein expression in at least one reference is a tissue, cell, or cell pellet sample sample, wherein the at least one reference sample or antigen binding which is not sensitive to treatment with an anti-FOLRl antibody fragment thereof, determined in wherein a FOLRl staining intensity score for the tumor tissue sample step (b) that is higher than the reference value identifies the tumor as being sensitive binding fragment thereof, and treatment with an OLRl antibody or antigen for treatment wherein the anti-FOLRl dy or antigen g fragment thereof the amino acid sequence GYFMN (SEQ comprises (i) a heavy chain (HC) CDRl comprising the amino acid sequence RIHPYDGDTFYNQKFQG ID NO:6); a HC CDR2 comprising the amino acid sequence YDGSRAMDY (SEQ (SEQ ID NO:7); and a HC CDR3 comprising (LC) CDRl sing the amino acid chain sequence ID NO:8) and (ii) a light the amino acid sequence KASQSVSFAGTSLMH (SEQ ID N029); a LC CDR2 comprising RASNLEA (SEQ ID ; and a LC CDR3 comprising the amino acid sequence QQSREYPYT (SEQ ID NO] 1). or antigen binding
2. The method of claim 1, wherein the anti—FOLRl antibody amino acid HC variable domain comprising the nt thereof for treatment comprises (i) a the amino acid ce NO:3 and (ii) a LC variable domain comprising sequence of SEQ ID of SEQ ID N024 or 5. or binding
3. The method of claim 2, wherein the anti-FOLRl antibody antigen acid sequence fragment thereof for treatment ses (i) a HC comprising the same amino -68— d by the plasmid ted with the American as the amino acid sequence of the HC Type Culture Collection (ATCC) as PTA—10772 (ii) a LC comprising the same amino encoded by the d deposited with acid sequence as the amino acid sequence of the LC the ATCC as PTA-10773 or PTA—10774. with anti—FOLRI
4. A method of identifying as sensitive to treatment an a tumor immunoconjugate, the method comprising: tissue sample obtained from the (a) measuring the level of FOLRl expression in a tumor measuring ses the use of a detection method that tumor, n the intensity and staining mity in distinguishes between staining a FOLRI and staining uniformity in expressing cancer sample as compared to staining intensity one or more reference samples; the tumor tissue sample; and (b) determining a FOLRl staining intensity score for reference (c) comparing the FOLRI ng intensity score determined in step (b) to a value determined by measuring FOLRI protein expression in at least one reference is a tissue, cell, or cell pellet sample sample, wherein the at least one reference sample anti-FOLRI immunoconjugate, which is not ive to treatment with an determined in wherein a FOLRI staining intensity score for the tumor tissue sample identifies the tumor as being sensitive to step (b) that is higher than the reference value treatment with an anti—FOLRI immunoconjugate, for treatment has the formula (A) ~ (L) — wherein the anti-FOLRI immunoconjugate (C), wherein: thereof (A) comprises an anti—FOLRI antibody or antigen binding fragment amino acid sequence GYFMN (SEQ ID NO:6); a comprising (i) a HC CDRl comprising the RIHPYDGDTFYNQKFQG (SEQ ID NO:7); HC CDR2 comprising the amino acid sequence (SEQ ID N021 1), LC CDR3 comprising the amino acid sequence QQSREYPYT (L) comprises a linker, (C) ses a cytotoxic agent, and wherein (L) links (A) to (C).
5. The method of claim 4, wherein the anti-FOLRl antibody or antigen binding HC variable domain comprising the fragment thereof of the immunoconjugate comprises (i) a amino amino acid sequence of SEQ ID N023 and (ii) a LC variable domain comprising the acid sequence of SEQ ID NO:4 or 5. method of claim 5, wherein the anti—FOLRl antibody or antigen binding
6. The (i) amino a HC comprising the same fragment thereof of the immunoconjugate comprises HC encoded by the plasmid deposited with acid sequence as the amino acid ce of the acid sequence as the the ATCC as PTA—10772 and (ii) a LC sing the same amino PTA— the plasmid deposited with the ATCC as amino acid sequence of the LC encoded by 10773 or PTA-10774. wherein the linker is selected from the group
7. The method of any one of claims 4—6, a dicarboxylic acid based consisting of: a hydrophilic linker, and a eavable linker, linker. of: N- linker is selected from the group consisting
8. The method of claim 7, wherein the (SMCC); N—sulfosuccinimidyl 4- succinimidyl 4—(maleimidomethyl) cyclohexanecarboxylate (maleimidomethyl) cyclohexanecarboxylate (sulfoSMCC); N-succinimidyl—4—(iodoacetyl)- aminobenzoate (STAB); and N-succinimidyl—[(N-maleimidopropionamido)— tetraethyleneglycol] ester (NHS-PEG4—maleimide). wherein the linker is a cleavable linker.
9. The method of any one of claims 4—6,
10. The method of claim 9, wherein the ble linker is selected from the group consisting of: N-succinimidyl 4-(2-pyridyldithio)pentanoate (SPP); N—succinimidyl 4-(2- pyridyldithio)~2~sulfopentanoate (sulfo—SPP); inimidyl 4-(2-pyridyldithio)butanoate (sulfo—SPDB). (SPDB); and N-succinimidyl 4-(2—pyridyldithio)sulfobutanoate linker is N—succinimidyl 4—(2-
11. The method of claim 10, n the cleavable pyridyldithio)sulfobutanoate -SPDB). wherein the cytotoxic agent is selected from
12. The method of any one of claims 4-11, analog, iazepine, taxoid, CC— the group consisting of: a sinoid, maytansinoid dolastatin, 1065, CC-1065 analog, duocarmycin, duocarmycin analog, calicheamicin, and leptomycin derivative or a prodrug dolastatin analog, atin, tomaymycin derivative, of the cytotoxic agent. is a maytansinoid.
13. The method of claim 12, wherein the cytotoxic agent wherein the agent is N(2’)-deacetyl-N(2')-(3-
14. The method of claim 13, cytotoxic mercapto—l—oxopropyl)—maytansine (DMl) or N(2')—deacetyl-N(2')—(4-mercapto-4—methyl—1— tyl)-maytansine (DM4).
15. The method of claim 13, wherein the linker is N-succinimidyl 4-(2—pyridyldithio) sulfobutanoate (sulfo-SPDB), and wherein the cytotoxic agent is N(2')—deacety1—N(2')-(4- mercapto-4—methyl- l -oxopentyl)—maytansine (DM4). binding or
The method of claim 13, wherein the anti—FOLRl antibody antigen amino comprises (i) a HC comprising the same fragment f of the immunoconjugate with of the HC encoded by the plasmid deposited acid ce as the amino acid sequence amino acid sequence as the the ATCC as PTA—10772 and (ii) a LC comprising the same ATCC as PTA- the plasmid deposited with the amino acid sequence of the LC encoded by 774, wherein the linker is N—succinimidyl 4—(2—pyridyldithio) 10773 or the agent is N(2‘)~deacetyl—N(2')-(4- sulfobutanoate (sulfo—SPDB), and n cytotoxic mercapto—4-methyl—l —oxopentyl)-maytansine (DM4). is performed
17. The method of any one of claims 1-16, wherein the detection method is performed
18. The method of any one of claims 1—16, wherein the detection method using an automated . of claims 1—18, n the detection method is
19. The method of any one immunohistochemistry (IHC). is calibrated IHC that can distinguish
20. The method of claim 19, wherein the IHC different levels of FOLRl expression, _ 71 the tumor tissue sample is a formalin
21. The method of claim 19 or claim 20, wherein fixed paraffin embedded sample.
22. The method of any one of claims 1-21, wherein the detection method produces a for samples having weak FOLRl expression, moderate FOLRl range of staining intensity sion, or strong FOLRl expression. has a
23. The method of any one of claims 19-21, wherein the tumor tissue sample FOLRl expression by IHC. ng intensity score of l or greater for tissue sample has a staining uniformity
24. The method of claim 23, wherein the tumor for FOLRl expression that is heterogeneous. tissue sample has a staining uniformity
25. The method of claim 23, wherein the tumor for FOLRl expression that is homogenous. tissue wherein 25-75% of cells of the tumor
26. The method of any one of claims 19—21, of l or greater. sample have a staining intensity score of cells of the
27. The method of any one of claims 19-21, wherein greater than 75% score of l or greater. tumor tissue sample have a staining intensity has a
28. The method of any one of claims 19-21, wherein the tumor tissue sample for FOLRl sion by IHC. staining ity score of 2 or greater the tumor tissue sample has a ng uniformity
29. The method of claim 28, wherein for FOLRl expression that is heterogeneous. the tumor tissue sample has a staining uniformity
30. The method of claim 28, wherein for FOLRl expression that is homogenous. tissue wherein 25—75% of cells of the tumor
31. The method of any one of claims 19—21, of 2 or greater. sample have a staining intensity score of the
32. The method of any one of claims 19-21, n greater than 75% of cells score of 2 or greater. tumor tissue sample have a staining intensity 19~21, wherein the tumor tissue sample has a
33. The method of any one of claims by IHC. staining intensity score of 1, 2, 3, or 3+ for FOLRl expression tissue sample has a staining uniformity
34. The method of claim 33, wherein the tumor for FOLRl expression that is heterogeneous. tissue sample has a staining uniformity
35. The method of claim 33, wherein the tumor for FOLRl expression that is homogeneous.
36. The method of any one of claims 1-35, wherein the level of FOLRI expression is fragment thereof that Specifically measured using a detection antibody or antigen binding binds FOLRl. detection antibody or n binding fragment
37. The method of claim 36, wherein the the amino acid sequence GYFMN (SEQ ID thereof comprises (i) a HC CDRl comprising acid sequence GDTFYNQKFQG (SEQ NO:6); a HC CDR2 comprising the amino the amino acid sequence YDGSRAMDY (SEQ ID ID N027); and a HC CDR3 comprising FAGTSLMH N028) and (ii) a LC CDRl comprising the amino acid sequence KASQSVS the amino acid sequence RASNLEA (SEQ ID (SEQ ID N019); a LC CDR2 comprising N010); and a LC CDR3 comprising the amino acid sequence QQSREYPYT (SEQ ID detection dy or antigen binding fragment
38. The method of claim 36, n the the amino acid sequence of SEQ ID thereof comprises (i) a HC variable domain comprising N0:4 or the amino acid sequence of SEQ ID N0:3 and (ii) a LC le domain comprising detection antibody or antigen binding fragment
39. The method of claim 38, wherein the acid thereof comprises (i) same amino acid sequence as the amino a HC comprising the ATCC as PTA-10772 and (ii) encoded by the plasmid deposited with the sequence of the HC a LC comprising the same amino acid sequence as the amino acid sequence of the LC encoded by the plasmid deposited with the ATCC as 773 or PTA~10774.
40. The method of claim 36, wherein the ion antibody or antigen g fragment thereofis BN3.2.
41. The method of any one of claims 36—40, wherein the detection antibody or antigen binding fragment thereof comprises a detection reagent.
42. The method of claim 41, wherein the detection reagent is selected from the group and a luminophore. consisting of: an enzyme, a phore, a radioactive label, is ed from the group
43. The method of claim 42, wherein the detection reagent ine. consisting of: biotin, digoxigenin, fluorescein, tritium, and concentration of the detection
44. The method of any one of claims 36-43, wherein the about 3.8 ug/ml. antibody or antigen binding fragment thereof is about 0.9 to is an endometrial tumor.
45. The method of any one of claims 1-44, wherein the tumor is an ovarian tumor.
46. The method of any one of claims 1—44, wherein the tumor is a tumor of the
47. The method of any one of claims 1—44, wherein the tumor peritoneum. ImmunoGen, Inc. By the patent attorneys for the applicant CULLENS
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161471007P | 2011-04-01 | 2011-04-01 | |
US61/471,007 | 2011-04-01 | ||
NZ615742A NZ615742B2 (en) | 2011-04-01 | 2012-03-30 | Methods for increasing efficacy of folr1 cancer therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ711375A NZ711375A (en) | 2017-02-24 |
NZ711375B2 true NZ711375B2 (en) | 2017-05-25 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019202611B2 (en) | Methods for increasing efficacy of FOLR1 cancer therapy | |
AU2013237826A1 (en) | Methods for increasing efficacy of CD37-based therapy | |
NZ711375B2 (en) | Methods for increasing efficacy of folr1 cancer therapy | |
NZ615742B2 (en) | Methods for increasing efficacy of folr1 cancer therapy | |
EA041061B1 (en) | METHODS FOR IDENTIFYING CANCER AS LIKELY ANTI-FOLR1 REACTIVE IMMUNOCONJUGATE |